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Background: Depression is the most common co-occurring mental health disorder among 
persons with opioid use disorder (OUD). Psychiatric comorbidity can impact healthcare 
utilization, particularly emergency department visits and hospitalizations, as well as continuity of 
treatment for opioid use disorder. The objectives of this dissertation are to enhance 
understanding of characteristics and health conditions among persons with co-occurring OUD 
and depression, and to explore the role depression plays in healthcare utilization and continuity 
of buprenorphine treatment. 
Methods: Data were obtained from the Geisinger Health System (GHS), and included electronic 
health records for all healthcare encounters that occurred at any of the GHS facilities before the 
fall of 2019. In addition to electronic health records, ordered and dispensed prescription records 
were used. Adults 18 years old or older included in each of the study samples were recruited 
from one of Geisinger’s outpatient addiction treatment clinics and all had at least one recorded 
OUD diagnosis in their electronic health record. Differences in characteristics and other 
diagnoses between persons with and without depression were assessed by multivariable logistic 
regression. Propensity score weighted Cox regression survival analysis for recurrent events was 
used to assess the association between OUD with prior depression and healthcare utilization. 
Propensity score weighted logistic regression was used to estimate odds of 180-day retention and 
any treatment discontinuation, and propensity score weighted Cox proportional hazards 
regression was implemented to estimate the hazard of treatment gaps or discontinuation for those 
with and without prior depression. 
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Results: Forty-nine percent of adults with OUD had a lifetime depression diagnosis. Persons with 
co-occurring depression were more likely to be female and have other common medical 
conditions, as well as other mental health and substance use disorders, and/or at least one 
overdose or suicide attempt or ideation. Compared to OUD without prior depression, OUD with 
prior depression was associated with increased risk of emergency department visits that included 
a substance use disorder, suicidal ideation or suicide attempt and/or mental health disorder code. 
Any prior or past year depression was associated with increased risk of treatment gap and/or 
discontinuation and past year depression was associated with decreased odds of 180-day 
buprenorphine treatment retention. 
Conclusions: This dissertation highlights the complex healthcare needs of persons with co-
occurring opioid use and depressive disorders, and the particular importance of the integration of 
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1.1 Opioid overdose and opioid use disorder in the United States 
 
Between the years of 1999 and 2018, over 750,000 people died from a drug overdose in 
the United States, and 69.5% of the drug overdoses in the 2018 involved an opioid.1 This 
represents a 200% increase in the rate of opioid overdose deaths since 2000.2 Today, overdose 
remains the leading cause of injury death in the United States.3 In addition to mortality, opioid-
related morbidity has increased substantially. The rate of inpatient hospitalization related to 
opioid misuse has increased over 150% since the 1990s4 and the rate of opioid-related 
emergency department visits has increased by 99% since 2005.5 While we have observed this 
increase in fatal and non-fatal overdose due to opioids, differing trends in the use of types of 
opioids exist. In the early 2000s, most opioid-related deaths were due to prescription opioids. 
Between 2000 and 2014, prescription opioid death rates increased from 1.5 to 5.9 deaths per 
100,000 persons.6 Opioid prescribing rates were also increasing during this time with 72.4 
prescriptions per 100 persons in 2006 to 81.2 prescriptions per 100 persons in 2010. Although 
opioid prescribing rates have decreased in recent years, the prescription rate remains high when 
compared to rates from the late 1990s.7 Over the past 10 years, the use of heroin and deaths due 
to heroin overdose have increased substantially. From 2000 to 2013 rates of heroin overdose 
death quadrupled and continued to increase.8 In 2017, almost 500,000 adults reported using 
heroin in the past year and the heroin overdose death rate was 5 per 100,000 adults in the US.9,10 
Most recently, there has been a surge in deaths due to fentanyl and other synthetic opioids (other 
than methadone); the number of deaths increased approximately 45% from 2016 to 2017.9  
In 2018, 10.3 million people 12 years old or older reported using opioids in a way not 
directed by a health provider.11 Among these 10.3 million adults, 9.9 million (97.1%) reported 
using prescription opioids and 808,000 (7.9%) reported any heroin use in the past year. Two 
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million people at least 12 years old in the US had an opioid use disorder (OUD), including heroin 
and/or prescription opioids, in 2018. This percentage is similar to that of 2016 and 2017, but 
lower than the proportion of adults with an opioid use disorder in 2015.11 Opioid use disorder is 
defined by the DSM-5, as problematic pattern of opioid use that leads to clinically significant 
impairment and/or distress. A number of criteria are used to diagnose an opioid use disorder. 
These criteria fall into four groups, including impaired control (e.g. craving), social impairment 
(e.g. reduction in other social, occupational or recreational activities due to opioid use), risky 
drug use (e.g. putting oneself in harm), and physiological problems (e.g. tolerance and 
withdrawal).12 
1.2 Substance use and mental health comorbidity: opioid use disorder and depression 
 
Substance use disorders are more prevalent among adults with mental health disorders 
compared to adults without mental health disorders.13 In 2018, 9.2 million adults in the US had 
co-occurring past-year mental health and substance use disorders, corresponding to 3.7% of 
adults in the US.11 Further, among adults with a substance use disorder, 47.7% had a past-year 
mental health disorder.11 Among persons with opioid use disorder, 64.3% had any mental illness 
in the past year and 26.7% had a serious mental illness according to the 2015-2017 National 
Survey on Drug Use and Health.14  
Major depressive disorder is among the most common mental illnesses that co-occur with 
opioid use disorder. In studies using US national survey data, lifetime prevalence of co-occurring 
OUD and major depressive disorder (MDD) among individuals with OUD has been shown to be 
as high as 50-60%.15,16 Among treatment seeking or enrolled populations, current prevalence of 
MDD is 27% among persons in treatment for non-medical prescription opioid use17 and 19.4% 
among patients receiving buprenorphine/naloxone treatment.18  
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Mental health disorder comorbidity is associated with lower reported quality of life and 
an increase in severity of mental health and substance use symptoms.19,20 Further, persons with 
co-occurring substance use and mental health disorders face increased barriers to accessing 
treatment, and experience challenges with substance use treatment completion.21–23 Particularly 
with opioid use disorder and depression, comorbid depression is associated with increased risk of 
opioid misuse, overdose and suicide.21,24–28  
Co-occurring mental illness also impacts healthcare service utilization including 
increased emergency department use among persons with substance use disorders.29,30 Among 
individuals with OUD, the increased use of emergency department services is potentially linked 
to unmet need for treatment of depression.31 
1.3 Opioid agonist treatment for opioid use disorder 
 
The use of opioid agonist medications is considered to be the standard of care for OUD.32 
Two types of opioid agonist medications are used to treat opioid use disorder- methadone and 
buprenorphine. Methadone, a full agonist, activates opioid receptors and works to reduce opioid 
cravings and withdrawal symptoms.33 Methadone is taken orally once per day and is typically 
dispensed through Opioid Treatment Programs (OTPs). Methadone has been used since the 
1960s; approximately 21-25% of clients at substance use treatment facilities with OTPs receive 
methadone each year.34 Buprenorphine is a partial opioid agonist at the mu receptor and an 
antagonist at the kappa receptor. Like methadone, buprenorphine reduces craving and 
withdrawal symptoms and does not produce euphoria.33 Buprenorphine was approved as a 
treatment for opioid use disorder by the Food and Drug Administration in 2002 (tablet-form) and 
is dispensed by medical providers who have a waiver to prescribe buprenorphine.34 Non-
extended release buprenorphine can be taken orally or sublingually and typically taken once or 
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twice daily.33 The percentage of substance use outpatient treatment facilities in the US that offer 
medication-based treatment for opioid use disorder increased from 20% in 2007 to 36.1% in 
2016.35 A larger increase was found for buprenorphine with 14.9% of facilities in 2007 to 25.4% 
in 2016, compared to methadone which was offered at 9.4% of treatment facilities in 2007 and 
10.3% in 2016. This same study found that in 2016, only 6.1% of facilities offered all three 
approved medications (methadone, buprenorphine and naltrexone) to treat opioid use disorder.35 
Another study that assessed information about healthcare providers waivered to prescribe 
buprenorphine found the prevalence of waivered prescribers increased from 3.8 to 17.3 per 
100,000 persons in 2017. However, this corresponds to less than 10% of all primary care 
providers in the US.36 
Opioid agonist treatment (OAT) is associated with increased treatment retention and a 
decrease in the use of opioids as well as other adverse effects of OUD including overdose deaths, 
criminal justice involvement, and transmission of HIV and Hepatitis C.27,37–41 Despite evidence 
supporting the use of OAT, a small proportion of adults with OUD receive OAT42,43 and among 
those who do receive it, a number of challenges exist including low adherence and treatment 
retention rates, as well as inadequate dosing and stigma associated with OAT.33,44–46 
1.4 Depression and opioid agonist treatment 
 
Psychiatric comorbidities are a known contributor to reduced access to substance use 
disorder treatment, lower retention and poorer outcomes among adults with substance use 
problems.20–23,47 However, research on the effects of psychiatric comorbidity on OAT does not 
necessarily align with the broader relationship between psychiatric comorbidity and substance 
use treatment. Existing studies have found no significant relationship between psychiatric 
comorbidity and early discontinuation of buprenorphine treatment.48,49 Another found no 
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association between psychiatric comorbidity and methadone or buprenorphine non-completion 
and weak association with time to attrition regardless of the type of opioid for which a client was 
admitted for.22 Others show a positive association, with psychiatric comorbidity associated with 
greater odds of continuous buprenorphine treatment for at least one year50 and a decreased 
likelihood of opioid use at 12 weeks of buprenorphine treatment; however this difference was not 
observed at 24 weeks.51  
Existing evidence on the association between depression and OAT is also not entirely 
consistent.52 Some studies have found positive treatment outcomes associated with depression. 
For example, Gerra and colleagues found that patients who remained in buprenorphine treatment 
at 12 weeks compared to those who dropped out had a higher rate of depression at baseline.53 
Dreifuss and colleagues assessed the impact of pre-treatment characteristics on 
buprenorphine/naltrexone treatment and found that lifetime depression was associated with 
prescription opioid abstinence at week 12 of treatment.54 Although a secondary analysis using 
data from the same randomized controlled trial did not find an association between reduction of 
depression symptoms during treatment and opioid abstinence at the 12 week follow-up.55 
Another study found no significant association between depression and buprenorphine treatment 
outcomes.56 Additionally, among those with co-occurring depression who also received 
antidepressant treatment, there was no clear difference in OAT drop-out or drug use among those 
receiving antidepressant medications and those receiving placebo.57 The association between 
depression and buprenorphine continuity is complex and likely differs from other mental health 
disorders because of antidepressant effects of  buprenorphine.58,59 However, limitations of 
existing studies include grouping depression into overall psychiatric comorbidity and short 
length of treatment follow-up. 
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1.5 Overdose risk: role of opioid agonist treatment and co-occurring depression 
 
Opioid agonist treatment is associated with a reduction in risk of overdose mortality 
among individuals with OUD.40,41,60 Risk of overdose mortality is highest immediately following 
cessation of treatment.40 Periods in methadone or buprenorphine treatment are associated with 
reduced hazard of opioid overdose compared to periods in treatment that do not involve 
medications. However, compared to periods in non-medication treatment, periods after discharge 
from methadone or buprenorphine treatment have similar risk of overdose indicating the 
importance of treatment retention.60 In addition, mental health hospital admissions and 
admissions related to self-harm are associated with increased risk of fatal opioid overdose 
following OAT.61 Further, depression is a risk factor of overdose, as well as suicide.24,28 
According to the National Survey on Drug Use and Health, people who use opioids regularly 
were 75% more likely to create a plan for suicide and two times as likely to attempt suicide 
compared to those who did not report using opioids.28 It is also estimated that 21-33% of 
overdose deaths are intentional.28,62,63 These findings highlight the need to understand the role of 
depression in continuity of opioid agonist treatment, which may in turn highlight ways to 
mitigate both risk of overdose and intentional self-harm among persons with co-occurring opioid 
use disorder and depression. 
1.6 Opioid epidemic in Pennsylvania 
 
Pennsylvania, where data for this dissertation comes from, is among the states with the 
highest rates of overdose deaths, with an age-adjusted drug overdose death rate of 36.1 per 
100,000 compared to the national rate of 20.7 in 2018.64 Sixty-five percent of drug overdose 
deaths in Pennsylvania involved an opioid in 2018.65 Between the years of 1999 and 2016, 
opioid-related mortality rate in Pennsylvania increased 50% per year.66 This high rate is 
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widespread, with 78% of counties in the state having an overdose death rate higher than the 
national average in 2016.67 However, there are county-wide differences in rates of overdose 
death. Six of the top ten counties with the highest rates are rural and the highest concentration of 
deaths are in the central and eastern parts of the state.68 Trends in type of opioid used are similar 
to national trends. In 2018, most deaths were due to fentanyl and fentanyl analogs, followed by 
heroin and prescription opioids.65 In regard to characteristics of those who died from a drug-
related overdose, 29% were between the ages of 25 and 34 years, 70% were male and 79% were 
non-Hispanic white.68 Although not specific to opioid use disorder, 82.5% of adults with a 
substance use disorder, other than alcohol use disorder, did not receive past year treatment 
(annual average, 2010-2014).69 
To get a better understanding of potential influential factors contributing to the high rates 
of opioid overdose in the state, it is important to explore structural and social determinants of 
health in the state, including economic stability and opportunity, access to healthcare, as well as 
social and community contexts. In Pennsylvania, the median household income is $59,449 and 
12.2% of the population is in poverty, both of these estimates are similar to the US as a whole. 
However, lower income and higher rates of poverty are heavily concentrated in the middle of the 
state where most counties are rural.70 Twenty-one percent of the state is rural71 and evidence 
from across the US suggests that rural areas have suffered from a heavy burden of opioid use 
disorder. This is impacted by many factors at the macro, local and micro levels. Of particular 
relevance, is the lack of access to health care, including medications to treat opioid use 
disorder.72 




The Geisinger Health System (GHS) is a healthcare system that serves 38 counties in 
central, south-central and northeastern Pennsylvania. Within GHS, there are primary and 
specialty care clinics, free-standing community practice clinics, and over ten hospitals. The 
combined annual volume of emergency visits is over 250,000. GHS is also its own health 
insurance provider- Geisinger Health Plan, but provides care for all payer groups (e.g. Medicare, 
Medicaid, private health insurance). GHS provides health insurance to over 0.5 million 
members: approximately 50% of GHP’s total membership is composed of Medicaid or Medicare 
members and approximately 40% of patients treated by the Geisinger Clinic also have Geisinger 
Health Plan coverage.73  
To address the opioid crisis in the Geisinger Health coverage area, Geisinger opened four 
outpatient addiction treatment clinics between the years of 2017 and 2019 that offer medications, 
including buprenorphine and naltrexone to treat opioid use disorder. Since the opening of the 
first clinic in 2017, at least 2,700 patients with opioid use disorder have received treatment. The 
primary treatment model includes buprenorphine or naltrexone to treat OUD, as well as other 
medical interventions for detoxification and withdrawal, counseling services and care 
coordination.74 Treatment protocols follow those of the American Society of Addiction 
Medicine. As of 2019, the average length of engagement across all patients (opioid use and 
alcohol use disorders) is approximately 220 days. Early data from the clinics show a reduction in 
all-cause mortality for patients treated for OUD, as well as improvements in other health 
domains (mental health, employment and social) according to the Addiction Severity Index.74  
1.8 Prior studies assessing OUD and overdose using Geisinger Health System data 
 
  A few studies have used Geisinger Health System data to explore opioid use and related 
problems. Two studies assessed patterns of healthcare utilization73 and risk factors25 associated 
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with opioid overdose. Related to the study questions of this dissertation, one study that explored 
characteristics of persons who had experienced an overdose, found that 65% of patients had a 
mental illness prior to first overdose in their health records.25 Interestingly, these researchers 
found that having a mental health disorder prior to first overdose was associated with a decrease 
in odds of death one year post-overdose.25 In another study exploring patterns of healthcare 
utilization and costs of medical care before and after an overdose, Maeng and colleagues 
observed increases in emergency department visits, acute inpatient admissions and total medical 
costs occurred in the 1-2 years prior to opioid overdose that persisted following an overdose.73 
More specific to patients treated for chronic pain, two studies found that the lifetime prevalence 
of any prescription opioid use disorder was 41.3% and that major depression was associated with 
OUD.75,76 
1.9 Summary and specific aims 
 
 As health systems like Geisinger work to expand treatment for OUD to reduce overall 
morbidity and mortality of these patients, more research is needed to understand their health 
needs, healthcare utilization and their course of opioid agonist treatment. This dissertation 
focuses on a vulnerable population of adults with co-occurring opioid use disorder and 
depression to understand how depression might play a role in healthcare utilization as well as 
continuity of buprenorphine treatment for OUD. All data came from the GHS, including 
electronic health records and prescription medication data ordered by health providers. All 
electronic health records for encounters and medication data within the GHS prior to the fall of 
2019 were available. 
 Patients included in the study samples of each of the dissertation aims include adults 
recruited from one of GHS’s four outpatient addiction treatment programs prior to the fall of 
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2019 to participate in a larger prospective study exploring clinical and genetic risk factors for 
opioid use disorder. The analyses conducted for this dissertation utilize this data to further our 
understanding of  healthcare utilization and the course of buprenorphine treatment among 
individuals with co-occurring opioid use and depressive disorders. The dissertation specific aims 
are as follows: 
Aim 1: The first study, Chapter 2 of this dissertation, describes person 
characteristics, health conditions and overall healthcare service utilization 
among patients with comorbid opioid use and depressive disorders, and 
assesses how these might differ among patients who have an opioid use 
disorder but no lifetime depressive disorder. This aim utilized all healthcare 
encounter data included in the electronic health records to describe patient 
characteristics, assess overall healthcare utilization and identify health conditions 
through diagnostic codes among adults with opioid use disorder and to compare 
differences between those with and without a co-occurring lifetime depressive 
disorder diagnosis. This study highlights important considerations when creating 
treatment plans and providing needed services for persons with co-occurring 
opioid use disorder and depression. 
Aim 2: The second study, Chapter 3, explores differences in emergency 
department encounters and inpatient hospitalizations, overall and specific to 
mental health and substance use disorders, across time between adults with 
opioid use disorder with and without co-occurring depression. Using 
healthcare encounter data, this aim compares risk of different types of healthcare 
encounters in the time period following a person’s first OUD diagnosis among 
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patients without a depression diagnosis prior to this OUD diagnosis and those 
with a depression diagnosis that preceded the OUD diagnosis. This study can help 
to inform potential unmet needs of persons with co-occurring opioid use disorder 
and depression based on differences in healthcare encounter utilization. 
Aim 3: The third study, Chapter 4, examines differences in buprenorphine 
treatment continuity and retention among persons with OUD with and 
without co-occurring depression. This aim included data on prescription 
medications ordered by GHS providers to assess differences in risk of gaps in and 
discontinuation of buprenorphine treatment for OUD among patients who 
initiated treatment at one of Geisinger’s outpatient addiction treatment centers, 
again comparing those with and without co-occurring depression. This study can 
























Chapter 2: Co-occurring depressive disorders among persons with 
opioid use disorder: Differences in characteristics, co-occurring 














Background: Among persons with opioid use disorder, the most common co-occurring mental 
health disorder is depression. Co-occurring depression has been linked to greater risk of opioid 
misuse, overdose and suicide. However, less is known about characteristics, health conditions 
and healthcare utilization of persons with co-occurring opioid use disorder and depression. 
Methods: This retrospective observational study included electronic health records (EHR) 
encounters from the Geisinger Health System in Pennsylvania that occurred prior to the fall of 
2019 of patients recruited from one of Geisinger’s outpatient addiction treatment clinics. All 
patients had at least one opioid use disorder (OUD) diagnosis in the EHR and were at least 18 
years old at the date of first OUD diagnosis (N=721). Co-occurring depression was defined by 
having at least one depression diagnosis code in the EHR. Multivariable binary and ordinal 
logistic regression was performed to assess differences in person characteristics, other behavioral 
health and medical diagnoses, and healthcare utilization between individuals with and without 
comorbid depression. 
Results: Forty-nine percent of the sample of persons with opioid use disorder had a lifetime 
depression diagnosis. Individuals with co-occurring depression were more likely to be female 
and have other medical conditions. Those with co-occurring depression were more likely to have 
other mental health and substance use disorders, as well as at least one overdose and/or suicide 
attempt or ideation. Persons with co-occurring disorders also had a greater number of outpatient 
and ED-related encounters compared to those with only OUD. 
Conclusions: Opioid use and depressive disorders commonly co-occur. The current study 
identifies other comorbidities and health risks that are associated with co-occurring OUD and 
 15 
depression, and highlights the need to consider these complex health needs when developing 

























In 2018, 9.2 million adults in the United States had both a substance use and a mental 
health disorder.11 Among adults with a substance use disorder almost half had a mental health 
disorder in the past year.10 This is also true among persons with opioid use disorder (OUD). A 
recent study using the data from the National Survey on Drug Use and Health, 2015-2017, found 
that 64.3% of adults with OUD had any mental illness and 26.9% had a serious mental illness.14 
This study also found differences by demographic characteristics, including females and non-
Hispanic white persons being more likely to have a co-occurring mental illness.  
More specifically, substance use disorders and major depression commonly co-occur. A 
systematic review and meta-analysis using data from community settings, as well as inpatient 
and outpatient treatment settings from 1990 to 2019, found that among persons with major 
depressive disorder, alcohol use disorder was the most prevalent, followed by a substance use 
disorder involving drugs other than cannabis.77 More limited information exists for the 
prevalence of depression among people with OUD. In studies using US national survey data, the 
lifetime prevalence of co-occurring OUD and major depressive disorder (MDD) has been shown 
to be as high as 50-60%.15,16 In OUD treatment seeking or enrolled populations, current 
prevalence of MDD ranges between 20-30%.17,18 
Psychiatric comorbidity among persons with substance use disorders is associated with 
reduced health-related quality of life, severity of mental health and substance use symptoms, and 
increased utilization of the emergency department.19,78 This comorbidity is also associated with 
increased barriers to substance use and mental health treatment, and worse substance use 
treatment outcomes.20–23 Specific to the relationship between opioid use disorder and depression, 
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co-occurring depression is associated with increased risk of opioid misuse, as well as non-fatal 
and fatal overdose and suicide.21,24–28 
Despite extensive research examining co-occurring mental health and substance use 
disorders, most prior research on the burden and service use among individuals with such 
comorbidity has examined psychiatric comorbidity overall and fewer studies have explored 
specific co-occurring disorders, including opioid use disorder and depression. Because of this, 
we know less about the characteristics, additional health conditions and overall engagement with 
the healthcare system of persons with co-occurring opioid use disorder and depression, in 
particular, as compared to those who have opioid use disorder without a depressive disorder. As 
we continue to create policies and services to address the opioid crisis in the US, increasing our 
understanding of this comorbidity will play a critical role in enhancing services for individuals 
with both OUD and depression. To address this gap, the current study aimed to describe 
characteristics and overall healthcare service utilization among patients with co-occurring opioid 
use and depressive disorders, and assess how these might differ among patients who have an 
opioid use disorder but no lifetime depressive disorder. 
2.2 Methods 
 
Study design and sample selection 
Data for this retrospective observational study were drawn from electronic health records 
(EHR) from the Geisinger Health System in Pennsylvania. The sample included EHR for all 
encounters that occurred within the Geisinger Health System prior to the fall of 2019 of patients 
who were recruited from one of Geisinger’s medication-based treatment clinics to participate in a 
larger prospective study that aims to assess clinical and genetic risk factors for opioid use 
disorders. In addition to EHR, data on dispensed medications were used. Dispensed medication 
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history was extracted from Surescripts and includes a patient’s dispensed medication history 
inside and outside of the Geisinger system. Medication information was available for most, but 
not all patients (n=697, 97%). Among these patients, the prior 24 months of dispensed 
medications from the requested date was provided. 
The study sample was limited to patients who had an opioid use disorder diagnosis as 
defined by having at least one International Classification of Diseases ninth or tenth revision 
(ICD-9 or ICD-10) diagnostic code in their records and were at least 18 years old at the date of 
their first OUD diagnosis. The current study does not qualify as human subjects research as 




Opioid use and depressive disorder diagnoses. All patients in the study population had 
opioid use disorder. Patients were defined as having co-occurring opioid use and depressive 
disorder if they had at least one ICD-9 or -10 diagnosis code for a depressive disorder in the 
EHR. To ensure that our results did not change with a stricter case definition, we also conducted 
sensitivity analyses using a criterion of at least three ICD codes for depression over the study 
period to identify patients with depressive disorder. 
A comprehensive list of all ICD-9 and -10 code used for each diagnosis is included in 
Supplemental Table 2.1. Inclusion of ICD codes was based on previous literature.25,27,79–85 
Dependent variables 
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Opioid overdose included all accidental and non-accidental poisoning codes involving 
opioids, not including codes specific to adverse effects of an opioid. Other mental disorder 
diagnoses were defined by ICD codes related to all non-depressive mental disorders.  
Other substance use includes all substance use disorder codes other than opioid use 
disorder. Chronic pain includes ICD codes for chronic pain. To define other medical diagnoses, 
codes were included for hypertension, diabetes mellitus, and disorders of the airway (chronic 
obstructive pulmonary disease (COPD) and asthma). Two suicide-related diagnoses were 
included, including attempts and ideations based on corresponding codes. To further understand 
the potential impact of a suicide attempt or ideation diagnostic code on diagnosis of depression, 
we explored the number of suicide attempt/ideation diagnostic codes that occurred before the 
date of the first depression diagnosis code, on the same date, or on a date following the first 
depression code. Of the 96 patients with at least one suicide attempt or ideation code, 49% had a 
depression code prior to the suicide diagnosis code. Thirty percent received these diagnoses on 
the same date, and 21% received a diagnosis for depression on a date following the suicide 
attempt/ideation diagnosis. 
Dispensed medications. A patient was identified as having one or more dispensed 
buprenorphine prescriptions if at least one dispensed buprenorphine prescription was present in 
their record. A patient was identified as having one or more dispensed antidepressant 
prescriptions if at least one dispensed antidepressant medication was present. 
Healthcare service utilization. The total length of care within the Geisinger Health 
System was calculated in years based on the first and last encounter dates within each record. We 
also calculated the total number of outpatient (OP), inpatient (IP) and emergency department 
(ED) encounters, as well as the number of OP, IP and ED encounters per year. Encounters that 
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were coded as ED to IP in the EHR were included in the ED-related visits for analyses because 
the initial contact was through the emergency department. For each encounter type, the total 
number was calculated, as well as the count within categories based on overall distribution 
across patients.  
Demographic information. Patient demographic measures included within or derived 
from the EHR included sex, age at first OUD diagnosis, race, ethnicity, marital status and 
insurance coverage through the Geisinger Health Plan as of the date of consent for the larger 
study. Patients’ age at first OUD diagnosis was categorized into the following age groups: 18-29, 
30-39, 40-49, and 50 or older. 
Analyses 
First, length of time between first and last encounters, number of encounters per year, 
demographic characteristics, lifetime diagnoses for each condition, lifetime dispensed 
buprenorphine and antidepressant medications, as well as outpatient, inpatient and emergency 
department encounters were examined for the overall sample population, and separately for the 
OUD-only and co-occurring OUD and depression subgroups. Second, univariate associations 
between co-occurring OUD and depression and each dichotomous or categorical variable were 
examined using logistic regression models. To identify differences in characteristics, other 
comorbid conditions and health service use between the two groups, multivariable binary and 
ordinal logistic regression analyses, adjusting for age, sex, race, ethnicity, years between first and 
last EHR encounter and number of encounters per year were conducted. Multivariable models 
for healthcare service use additionally adjusted for other substance use diagnosis, other chronic 
pain diagnosis, other HIV/Hep C diagnosis, other medical comorbidity diagnoses. Confidence 
intervals were assessed at the 95% level and the measure of association was considered to be 
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Characteristics and health service utilization of the study sample 
A total of 721 persons had at least one opioid use disorder diagnosis and were 18 years or 
older at the time of their first OUD diagnosis. Of these, 354 (49%) also had at least one 
depression diagnosis in their lifetime. Characteristics of the study sample are presented in Table 
2.1, overall, as well as separately for patients who only had an OUD diagnosis and those with 
lifetime co-occurring OUD and depression. In the total sample, 52.4% were male and over 70% 
were under the age of 40. Ninety-nine percent of the sample was white and 85% of patients were 
not married. About 50% of all patients were enrolled in the Geisinger Health Plan. The mean 
number of years between the first and last Geisinger encounter across all patients was 11.7 years 
(Table 2.2). The mean number of all outpatient, inpatient and emergency department encounters 
was 51.7, with an average of 7.9 encounters per year. 
Differences between OUD with and without co-occurring depression  
There were a number of differences between persons diagnosed with OUD who had 
versus did not have co-occurring depression (Table 2.1). Those with co-occurring OUD and 
depression were more likely to be female (adjusted odds ratio (aOR)=0.53; 95% CI 0.38, 0.72), 
but did not differ on other demographic characteristics. Those with co-occurring OUD and 
depressive disorders had higher odds of having another medical comorbidity (aOR 2.00; 95% CI 
1.42, 2.81). This was also the case for other mental (aOR 7.78; 95% CI 5.27, 11.54) and 
substance use (aOR 5.47; 95% CI 3.13, 9.55) disorders. There were also significant differences 
among groups in the prevalence of overdose, including those specific to opioids and other types 
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of overdose. Patients with co-occurring OUD and depression had higher odds of having at least 
one opioid overdose (aOR 3.38; 95% CI 1.79, 6.39), as was also the case with non-opioid 
overdose (aOR 2.75; 95% CI 1.51, 5.04). Similar results were also found for suicide attempt and 
ideation. Co-occurring disorders were associated with greater odds of having at least one suicide 
attempt and/or ideation code. Finally, while the majority of all patients had at least one dispensed 
buprenorphine prescription, those with co-occurring depression had decreased odds of at least 
one dispensed buprenorphine prescription (aOR 0.51, 95% CI 0.27, 0.94). Those with co-
occurring depression were more likely to have received at least one dispensed antidepressant 
medication (aOR 5.90, 95% CI 3.89, 8.95) (Table 2.1). 
The mean length of time in years between the first and last Geisinger encounter was 
greater for patients with co-occurring disorders (14.1 years vs. 9.5 years), as depicted in Table 
2.2. Those with co-occurring disorders also had a greater number of outpatient and ED-related 
encounters compared to those with only OUD, after accounting of total length of time in the 
EHR as well as number of encounters per year.  
2.4 Discussion 
 
In this sample of patients with an opioid use disorder from a large integrated healthcare 
system in central Pennsylvania, almost half also had a lifetime diagnosis of depression. Further, 
after adjusting for length of time between first and last encounter in the EHR and number of 
encounters per year, we found significant differences between patients with only OUD and those 
with co-occurring OUD and depressive disorders with regard to other comorbidities, adverse 
health outcomes, and healthcare service utilization. Of particular concern, patients with lifetime 
co-occurring opioid use and depressive disorders had increased odds of having one or more 
opioid or non-opioid overdoses. These patients also had increased odds of having a code for 
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suicide attempt or suicide ideation within their electronic health records compared to patients 
who had an opioid use disorder but did not have a diagnosis for depression. This is consistent 
with previous research indicating that having a psychiatric comorbidity is associated with 
increased risk of non-fatal and fatal overdose,26,27 as well as suicide.28 
Other common medical conditions including hypertension, diabetes, COPD and asthma 
were also more prevalent among people with a co-occurring depressive disorder. These 
comorbidities have been shown in populations of people with both OUD and depression 
separately, but have been explored less frequently among those who have co-occurring disorders. 
Australian Treatment Outcome Study investigators found that overall physical and mental health 
was worse among heroin use disorder patients with comorbid depression than those without this 
comorbidity.86 While not statistically significant in the adjusted models, chronic pain is another 
important comorbidity in this population. Chronic pain is common among persons with OUD 
and depression,87–89 and among people with non-cancer chronic pain, depression has been shown 
to moderate the relationship between increased pain severity and opioid use.90 The intersection 
between opioid use disorder, depression and chronic pain has significant implications for 
understanding the course and outcomes of all three conditions, as well as treatment plans to 
improve the health and well-being of individuals who are impacted. Integrated care models exist 
to address the complex healthcare needs of people who have co-occurring disorders, including 
integrating substance use and mental health care into primary care settings, integrating primary 
care into substance use and mental health services, as well as health homes which provide 
coordinated care for people with multiple health conditions, including substance use and mental 
health disorders.91 The results of the current study underscore the importance of easily accessible 
integrated care for this population. 
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Persons with co-occurring opioid use and depressive disorders also utilized the 
emergency department in greater frequency, compared to those without a co-occurring 
depressive disorder. Opioid use and depressive disorders are associated with more frequent 
emergency department use, and present unique health risks including overdose.27,92,93 This might 
be related to severity of opioid use or depressive disorder and other added comorbidities 
experienced by these individuals. Additionally, adverse outcomes of depression and opioid use 
disorder, including suicide ideations and attempts, and non-fatal overdose could influence 
service use.94–96 Greater use of emergency services in this comorbid group may also be related to 
the larger number and types of barriers to accessing needed healthcare that individuals face, 
including cost of care, inconvenience of service location or hours, as well as negative views from 
others.23 Whatever the reasons for the increased use of services in the group of patients with co-
occurring opioid use and depressive disorders, our results suggest that this population 
experiences a greater burden of OUD and would likely benefit from highly-integrated services 
that meet their multiple needs. Integrated care creates the opportunity for greater provider 
coordination and could prevent frequent use of emergency and inpatient services, and improve 
patients’ quality of life—opportunities that may be far less available in other health care settings 
where substance use treatment, mental health services, and other medical care are typically 
separate and far less integrated than in the Geisinger Healthcare System. 
Limitations 
There are many advantages of using EHR, including the ability to follow patients 
longitudinally and the capacity to assess real-world utilization patterns. However, there are also a 
number of limitations that need to be acknowledged. For information on diagnoses, this study 
relies on ICD codes and provider documentation of these codes, which could be influenced by 
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provider diagnostic and practice styles, as well as requirements of health insurance billing. 
Related to this point, EHR data is not collected for research purposes and thus EHR diagnoses 
using ICD codes may differ from those collected in a more traditional diagnostic interview. 
However, because this population was recruited from an outpatient substance use treatment 
clinic, addiction specialists verified the OUD diagnosis. Additionally, we were only able to 
assess characteristics and diagnostic codes included in the EHR; there are many other health 
system- and person-level factors that that we were not able to assess. It is possible that 
individuals received care at one point or another from a non-Geisinger healthcare system, or 
could have died during the study period, which would not be captured in the EHR used for this 
study. Additionally, the time observed within the EHR for each person is not consistent. 
However, we did adjust for length between first and last visit and number of encounters per year. 
The sample of the current study includes almost exclusively white patients from rural 
Pennsylvania. Because of this, the results may not generalize to more racially diverse and urban 
populations. Finally, this sample is limited to persons who were seeking care at a medication-
based treatment program for opioid use disorder. Therefore, the results might also not generalize 
to persons who do not have access to these clinics and may face greater barriers accessing care. 
Conclusions 
Opioid use and depressive disorders commonly co-occur. As we continue to develop 
policies and services to reduce the morbidity and mortality associated with the opioid epidemic, 
we should also be considering ways to address comorbid mental health disorders, and depression 
in particular. This study highlights the characteristics and health service use patterns of 
individuals with co-occurring opioid use and depression that are essential to consider when 
creating treatment plans and providing needed services. 
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 % % % Unadjusted OR (95% CI)c Adjusted OR (95% CI)c,d 
Sex      
  Female 47.6 39.2 56.2   
  Male 52.4 60.8 43.8 0.50 (0.37, 0.67)*** 0.53 (0.38, 0.72)*** 
Agee      
  18-29 36.6 36.2 37.0 1.00 1.00 
  30-39 36.8 40.0 34.5 0.87 (0.62, 1.22) 0.82 (0.56, 1.18) 
  40-49 15.4 14.7 16.1 1.07 (0.69, 1.67) 1.00 (0.62, 1.62) 
  50 or older 11.2 10.1 12.4 1.21 (0.73, 1.99) 1.28 (0.75, 2.21) 
Race      
  Other 0.97 1.1 0.9   
  White 99.0 98.9 99.1 1.29 (0.29, 5.80) 0.33 (0.03, 3.42) 
Ethnicity      
  Hispanic or Latino 2.5 3.3 1.7   
  Not Hispanic or Latino 97.5 96.7 98.3 1.96 (0.73, 5.28) 0.97 (0.31, 3.08) 
Marital status      
  Not Married 85.4 85.9 85.9   
  Married 14.6 15.1 14.1 0.93 (0.61, 1.40) 0.87 (0.55, 1.37) 
Geisinger insurance      
   No 46.9 49.3 44.5   
  Yes 53.1 50.7 55.5 1.21 (0.91, 1.63) 1.13 (0.82, 1.55) 
Opioid Overdosef      
  Zero 91.5 95.4 87.6   
  One or more 8.5 4.6 12.4 2.92 (1.64, 5.22)*** 3.38 (1.79, 6.39)*** 
Non-Opioid Overdoseg      
  Zero 90.6 95.4 85.6   
  One or more 9.4 4.6 14.4 3.46 (1.96, 6.13)*** 2.75 (1.51, 5.04)*** 
Other MH disorder dxh      
  Zero 37.2 60.5 13.0   
  One or more 62.8 39.5 87.0 10.25 (7.05, 14.90)*** 7.78 (5.27, 11.54)*** 
Other SU disorder dx      
  Zero 17.6 29.7 5.1   
  One or more 82.4 70.3 94.9 7.89 (4.67, 13.32)*** 5.47 (3.13, 9.55)*** 
 27 
Suicide attempt dx      
  Zero 94.6 98.4 90.7   
  One or more 5.4 1.6 9.3 6.19 (2.56, 14.95)*** 5.01 (2.01, 12.53)*** 
Suicide ideation dx      
  Zero 89.6 99.2 79.7   
  One or more 10.4 0.8 20.3 30.98 (9.66, 99.35)*** 35.62 (10.85, 116.89)*** 
Suicide attempt or ideation dx     
  Zero 86.7 97.6 75.4   
  One or more 13.3 2.4 24.6 12.96 (6.41, 26.21)*** 13.92 (6.71, 28.88)*** 
Chronic pain dx      
  Zero 69.6 76.3 62.7   
  One or more 30.4 23.7 37.3 1.91 (1.38, 2.64)*** 1.37 (0.95, 1.98) 
HIV or Hep C dx      
  Zero 81.1 84.7 77.4   
  One or more 18.9 15.3 22.6 1.62 (1.11, 2.37)* 1.34 (0.89, 2.01) 
Other med dxi      
  Zero 58.5 70.0 46.6   
  One or more 41.5 30.0 53.4 2.68 (1.97, 3.63)*** 2.00 (1.42, 2.81)*** 
Dispensed bup rx      
  Zero 8.2 6.3 10.0   
  One or more 91.8 93.7 90.0 0.61 (0.35, 1.05) 0.51 (0.27, 0.94)* 
Dispensed anti-dep rx      
  Zero 28.4 45.4 11.5   
  One or more 71.6 54.6 88.5 6.42 (4.34, 9.50)*** 5.90 (3.89, 8.95)*** 
***p<0.001, **p<0.01, *p<0.05 
a Opioid use disorder (OUD) 
b Opioid use disorder and Depression (OUD+DEP) 
c Odds of each characteristic, diagnosis, and dispensed medication in the OUD with depression group relative to the odds of each in the OUD 
without depression group; OR refers to odds ratio and aOR refers to adjusted odds ratio 
d Adjusted models include age, sex, race, ethnicity, number of encounters per year, and total length of care between first and last GHS 
encounter dates 
e  Age at first opioid use disorder diagnosis 
f  Includes any opioid poisoning ICD9 or ICD10 code 
g Includes any poisoning ICD9 or ICD10 code, not specific to opioids 
h Excludes depressive disorders, but includes other mood disorders (402, 55.3% have at least one mood disorder dx) 
i Includes hypertensive disease, diabetes mellitus, and other disorders of the airway (i.e. COPD and asthma) ICD9 or ICD10 codes 
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Table 2.2 Healthcare service utilization comparing patients with opioid use disorder with and without lifetime depression  
 Overall (N=721) OUD only (n=367) OUD+DEP (n=354)   




      
Number of GHS encountersa 51.7 (47.5) 32.7 (27.6) 71.5 (55.2) 2.19 (1.95, 2.47)*** 0.97 (0.83, 1.13) 
Number of encounters per year 7.9 (17.9) 10.1 (24.5) 5.7 (4.6) 0.57 (0.44, 0.73)*** 0.87 (0.73,1.03) 
      
 % % %   
Outpatient encounters      
  0-9 13.7 21.8 5.4 4.36 (3.30, 5.78)*** 2.06 (1.51, 2.82)*** 
  10-19 20.7 25.9 15.3   
  20-29 15.3 19.9 10.5   
  30-39 12.6 11.7 13.6   
  40 or more 37.7 20.7 55.4   
Inpatient encounters      
  0 42.4 54.2 30.2 2.80 (2.12, 3.70)*** 1.22 (0.89, 1.68) 
  1-2 29.0 27.5 30.5   
  3 or more 28.6 18.3 39.3   
Emergency department encounters      
  0 19.7 27.8 11.3 2.97 (2.26, 3.92)*** 1.51 (1.11, 2.06)** 
  1-5 38.8 43.6 33.9   
  6-9 15.7 12.3 19.2   
  10 or more 25.8 16.4 35.6   
***p<0.001, **p<0.01, *p,0.05 
a Includes outpatient, inpatient and emergency department encounters 
b Models examined the odds of each healthcare service outcome in OUD with depression group relative to the odds of each healthcare service 
outcome in OUD without depression group 
c Adjusted models include age, sex, race, ethnicity, any other SU dx, any chronic pain dx, any HIV/Hep C dx, any other Medical dx, length of time in 









Supplemental Table 2.1 ICD 9 and ICD 10 codes used to define diagnoses  
Diagnosis categories Diagnosis Included 
Mental health and Substance use   
Opioid use disorder ICD9: 304, 304.0, 304.00-.02, 305.5, 305.50-.52 
ICD10: F11, F11.1, F11.10, F11.12, F11.120-.122, F11.129, F11.14, F11.15, 
F11.150-.151, F11.159, F11.18, F11.181-.182, F11.188, F11.19, F11.2, F11.20, 
F11.22, F11.220-.222", F11.229, F11.23-.25, F11.250-.251, F11.259, F11.28, 
F11.281-.282, F11.288, F11.29, F11.9, F11.90, F11.92, F11.920-.922, F11.929, 
F11.93-.95, F11.950-.951, F11.959, F11.98, F11.981-.982, F11.988, F11.99 
Depressive disorders ICD9: 296.2*, 296.3*, 300.4*, 311 
ICD10: F32*, F33*, F34.1 
Other substance use disorder ICD9: 303*, 304.1*, 304.2*, 304.3*, 304.4*, 304.5*, 304.6*, 304.8*, 304.9*, 
305.0*, 305.1*,305.2*, 305.3*, 305.4*, 305.6*, 305.7*, 305.9* 
ICD10: F10*, F12*-F19*, F55* 
Other mental health disorder  ICD9: 290*-296*, 297*-299*, 300*, 301*, 302*, 308*, 309* 
ICD10: F01*-F09*, F20*-F25*, F28*-F29*,  F31*, F34*, F39, F40*, F41.0, 
F41.1, F41.3, F41.8, F41.9, F42*-F45*, F48*, F50*-F52*, F54*, F59*, F60*, 
F63*-F69*, F99* 
Suicide attempt ICD9: E950*-E958* 
ICD10: T14.91*, X71*-X83* 
Suicide ideation ICD9: V62.84 
ICD10: R45.851 
Overdose  
Opioid overdose ICD9: 965, 965.0, 965.01, 965.09, E850.0, E850.2 
ICD10: T40.0X1*, T40.0X2*, T40.0X4*, T40.1-.4*, T40.6* 
Other drug overdose  ICD9: 965.1, 965.4, 965.5, 965.6*, 965.7-.9, 967*, 968*, 969*, 969.4, 970*, 
970.81 980*, 981, 982*, E850.3-.9, E851, E852*, E853*, E854*, E855.1, 
E858.8-.9, E860*, E862*, E980*, E980.0-.5 
ICD10: T39.011*, T39.012*, T39.014*, T39.091*, T39.092*, T39.094*, 
T39.4X1*, T39.4X2*, T39.4X4*, T39.8X1*, T39.8X2*, T39.8X4*, T39.91*, 
T39.92*, T39.94*, T40.5X1*, T40.5X2*, T40.5X4*, T40.7X1*, T40.7X2*, 
T40.7X4*, T40.8X1*, T40.8X2*, T40.8X4*, T40.901*, T40.902*, T40.904*, 
T40.991*, T40.992*, T40.994*, T41.0X1*, T41.0X2*, T41.0X4*, T41.1X1*, 
T41.1X2*, T41.1X4*, T41.201*, T41.202*, T41.204*, T41.291*, T41.292*, 
T41.294*, T41.3X1*, T41.3X2*, T41.3X4*, T41.41*, T41.42*, T41.44*, 
T42.3X1*, T42.3X2*, T42.3X4*, T42.4X1*, T42.4X2*, T42.4X4*, T43.601*, 
T43.602*, T43.604*, T43.621*, T43.622*, T43.624*, T43.631*, T43.632*, 
T43.634*, T43.641*, T43.642*, T43.644*, T43.691*, T43.692*, T43.694*, 
T43.8X1*, T43.8X2*, T43.8X4*, T43.91*, T43.92*, T43.94* 
Other medical   
Chronic pain  ICD9: 338.2*, 338.4,  
ICD10: G89.2*, G89.4 
HIV and Hepatitis C ICD9: 042, 070.41, 070.44, 070.51, 070.54, 070.71 
ICD10: B20, B17.1*, B18.2, B19.2* 
Other (includes hypertensive disease, 
diabetes mellitus, disorders of the 
airway-COPD and asthma) 
ICD9: 401*-405*, 205*, 490*-496* 










Supplemental Table 2.2 Predicted probabilities of number of outpatient, inpatient and emergency 
department visits comparing OUD without depression and OUD with depression 
 OUD only (n=367) OUD+DEP (n=354) 
 Predicted Probability [95% CI] Predicted Probability [95% CI] 
Outpatient encounters   
0-9 0.09 (0.01) [0.07,0.12] 0.05 (0.01) [0.03, 0.06] 
10-19 0.25 (0.02) [0.21, 0.29] 0.15 (0.02) [0.12, 0.19] 
20-29 0.23 (0.02) [0.19, 0.27] 0.19 (0.02) [0.16, 0.23] 
30-39 0.18 (0.02) [0.14, 0.21] 0.20 (0.02) [0.16, 0.24] 
40 or more 0.25 (0.02) [0.21, 0.30] 0.41 (0.03) [0.35, 0.47] 
Inpatient encounters   
0 0.43 (0.03) [0.37,0.49] 0.38 (0.03) [0.33, 0.44] 
1-2 0.36 (0.02) [0.32, 0.41] 0.38 (0.02) [0.33, 0.42] 
3 or more 0.20 (0.02) [0.16, 0.25] 0.24 (0.02) [0.19, 0.29] 
ED encounters   
0 0.15 (0.02) {0.12, 0.19] 0.11 (0.01) [0.08,0.13] 
1-5 0.52 (0.02) [0.48, 0.57] 0.47 (0.03) [0.42, 0.52] 
6-9 0.16 (0.02) [0.15, 0.22] 0.20 (0.02) [0.16, 0.23] 









































Chapter 3: Emergency department and inpatient service utilization 

























Background: In recent years, emergency department visits involving opioid overdose have 
increased. Co-occurring mental illness is associated with increased risk of overdose, as well 
greater emergency department utilization among persons with substance use disorders. Because 
depression is a common co-occurring mental illness among persons with opioid use disorder, this 
study aimed to assess the role of depression in the utilization of emergency department and 
inpatient services among persons with opioid use disorder. 
Methods: Electronic health records from the Geisinger Health System in Pennsylvania were 
obtained for patients who had at least one opioid use disorder diagnosis in their records (N=613). 
Co-occurring depression was defined by having a depression diagnosis prior to first opioid use 
disorder diagnosis. Propensity score weighted Cox regression survival analysis for recurrent 
events was used to assess differences in risk for healthcare service utilization comparing those 
with and without prior depression. 
Results: Compared to opioid use disorder without prior depression, opioid use disorder with prior 
depression was associated with increased risk of emergency department visits that included a 
substance use diagnosis, suicide ideation or attempt code, and/or other mental health disorder 
codes. 
Conclusions: Co-occurring depression is associated with greater risk of emergency department 
utilization related to effects of substance use and mental health disorders. This increased risk 
could be influenced by the unmet need for treatment, as well as complex treatment needs of 
persons with co-occurring opioid use disorder and depression. Further exploration is needed to 
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understand the role of depression in the use of these healthcare services and how integration of 

























Despite the small decrease in drug overdose deaths from 2017 to 2018 in the US, over 
65,000 people in the US died from an overdose in 2018 and 70% of these deaths involved an 
opioid.97 In the recent years of the US opioid crisis, the prevalence of opioid-related emergency 
department visits and inpatient hospitalizations have continued to increase. Between 2005 and 
2014, the rate of opioid-related inpatient hospitalizations increased 64.1% and opioid-related ED 
visits increased 99.4%.5 More recently from July 2016 to September 2017, emergency 
department visits that involved an opioid overdose increased by 30% in the US overall.98 
Emergency department utilization is of high importance because of potential implications related 
to greater symptom severity, inadequate management of health conditions, increased risk of 
hospitalization, as well as greater use of the health system overall.29 In regard to the opioid crisis, 
understanding emergency department use and inpatient hospitalizations among persons who use 
opioids is of particular value, as it can inform jurisdictions of potential changes in opioid-related 
consequences, including non-fatal and fatal overdose, and serve as an early intervention point for 
individuals who are most at risk.98,96,99  
Co-occurring mental illness is a contributing factor to increased emergency department 
utilization among people with substance use disorders.29,30 Mental illness among persons with 
opioid use disorder (OUD) is common,14 and in addition to impacts on healthcare service 
utilization, this comorbidity can lead to heighted risk of morbidity and mortality.19,25 Depression 
is the most common mental health disorder that co-occurs with OUD,18 and associated with risk 
of overdose and suicide in this population.25,26,28 There is also unmet need for treatment of 
depression among persons with substance use disorders, including OUD, with 55% of people 
with co-occurring major depressive episodes and substance use disorder reporting past year 
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treatment for depression.31 This unmet treatment need could be impacting the utilization of 
emergency department and inpatient services, as well as contribute to risk of adverse outcomes. 
Because of the increased prevalence of a co-occurring depressive disorder among adults 
with opioid use disorder, as well as the complex health needs, it is important to further explore 
how this population utilizes emergency department and inpatient healthcare services. Extensive 
literature exists that explores ED use among persons with substance use and mental illness 
broadly, but despite this, we know less about the specific role depression plays in the use of 
emergency department and inpatient services among persons with OUD. Further, limited 
information is available about specific reasons for the use of ED and inpatient services among 
those with co-occurring disorders, and more specifically those with OUD and depression. To 
address these gaps in our knowledge, this retrospective cohort study sought to understand the 
role of depression in healthcare service utilization among persons with opioid use disorder. This 
study aimed to explore differences in types of healthcare encounters, including emergency 
department and inpatient encounters overall and those specific to mental health and substance 
use disorders over a period of a number of years utilizing electronic health records from a large 
integrated healthcare system in Pennsylvania.  
3.2 Methods 
 
Study design and setting 
Data were drawn from the Geisinger Health System in Pennsylvania. The study sample 
included patients who were recruited from one of Geisinger’s four medication-based substance 
use treatment programs prior to the fall of 2019 to participate in a larger prospective study 
exploring clinical and genetic risk factors for opioid use disorder. All electronic health records 
for encounters within the Geisinger Health System prior to the fall of 2019 were available. 
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Electronic health records (EHR) were limited to adults with an opioid use disorder (OUD) 
diagnosis in their records, who were at least 18 years old on the day of their first OUD diagnosis 
and had at least 12 months of EHR data prior to their first OUD diagnosis code in the health 
records (N=613). An OUD diagnosis was determined according to International Classification of 
Diseases Ninth and Tenth Revisions Clinical Modification (ICD-9-CM and ICD-10-CM). A list 
of all diagnostic codes for OUD used in the study is included in Supplemental Table 3.1. All 
healthcare encounters, including outpatient, inpatient and emergency department visits within the 
Geisinger Health System, records that occurred prior to a person’s first OUD diagnosis date were 
used to define exposure groups. Encounter records that occurred on or after a person’s first OUD 
diagnosis date were included in time to event analyses. The final analytic dataset resulted in a 
total of 608 individual patients, who had encounters following their OUD diagnosis, with 21,058 
total encounters over an average of 872 days between first OUD diagnosis and last EHR 
encounter. Across all patients, the dates of first OUD diagnosis ranged from July 16, 1998 to 
August 9, 2019. Dates of last EHR encounter ranged from May 12, 2018 to September 20, 2019. 
The current study did not qualify as human subjects research as determined by Geisinger and 
Johns Hopkins Bloomberg School of Public Health Intuitional Review Boards. 
Independent and outcome measures 
 The primary exposure variable of interest was a depression diagnosis code prior to the 
date of first OUD diagnosis. This was defined in two ways: 1) Any depression diagnosis code 
prior to first OUD diagnosis; 2) Any depression diagnosis code within 12 months prior to first 
OUD diagnosis. Other covariates included the following: sex, age at OUD diagnosis date, race, 
ethnicity, mental illness (MI) (other than depression), substance use disorder (SUD) (other than 
opioid use disorder), HIV or Hepatitis C diagnosis, chronic pain diagnosis, and other common 
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medical diagnoses (hypertension, diabetes mellitus, and disorders of the airway (chronic 
obstructive pulmonary disease (COPD) and asthma), all prior to date of first OUD diagnosis. All 
medical and mental health and substance use diagnoses were defined using ICD 9 or 10 codes 
listed in Supplemental Table 3.1. Prior buprenorphine medication to treat opioid use disorder 
was also included by incorporating data from ordered prescriptions from Geisinger and 
dispensed prescriptions that could have been ordered inside or outside of the Geisinger Health 
System. For the purposes of our study, we categorized persons as having a buprenorphine 
prescription if they had at least one ordered or dispensed buprenorphine medication prior to first 
OUD diagnosis. 
 We assessed the following outcomes that occurred after a person’s first OUD diagnosis 
date: 1) All emergency department (ED) encounters; 2) Overdose-related ED encounters defined 
as having an opioid or non-opioid poisoning code at an ED encounter; 3) Suicide-related ED 
encounters defined as having a suicide attempt or ideation code at an ED encounter; 4) Mental 
illness-related ED encounter defined as having a mental health disorder code (including 
depression) at an ED encounter; 5) Substance use-related ED encounter defined as having a 
substance use disorder code (excluding OUD) at an ED encounter; 6) All inpatient (IP) 
encounters; 7) Mental illness-related IP encounters; 8) Substance use-related IP encounters; 9) 
All suicide (attempt or ideation) related encounters; 10) All overdose (opioid or non-opioid 
poisoning) encounters. 
Data Analyses 
Propensity score weighting. First, to account for potential confounding variables and to 
create exposure groups with balanced distribution of observed covariates, stabilized inverse 
probability of treatment weights (IPTW) for OUD with prior depression were calculated from 
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propensity scores derived using logistic regression. For all prior depression, propensity scores 
were constructed using patient characteristic variables at the date of origin (first date of OUD 
diagnosis) and relevant diagnoses, including other mental health disorders, other substance use 
disorders, medical conditions, HIV or Hepatitis C, and chronic pain, as well as any received 
buprenorphine prescriptions that occurred prior to the origin. For past year depression, only 
diagnosis codes that occurred with the year prior to first OUD diagnosis were included. After 
applying IPTW, we observed substantial reductions in differences in the distribution of 
covariates between the OUD without and OUD with prior depression groups. Crude and 
standardized differences in covariate proportions are presented in Supplemental Tables 3.2 and 
3.3. Absolute standardize differences are often used to examine covariate balance after applying 
propensity score methods. Two thresholds, 0.1 and 0.25 have been identified in prior research for 
identifying imbalance.100 After applying weights for all prior depression all standardized 
differences were less than 0.1. After applying weights for past year depression, the standardized 
difference for sex was greater than 0.25 and the absolute standard differences for age category 
40-49, past year mental health and substance use disorders, and past year buprenorphine were 
greater than 0.1 (Supplemental Table 3.3). To account for potential imbalance after applying 
weights, we also included these variables in the regression models for past year depression. 
Time to event models. We conducted a propensity score weighted Cox regression survival 
analysis for recurrent events. Risk set entry was the date of first OUD diagnosis and the exit date 
was the date of last encounter in the EHR. To assess the association between OUD with prior or 
past year depression and each outcome, we utilized an extension of the Cox proportional hazards 
model: the Prentice, Williams and Peterson (PWP) model to estimate the crude and stabilized 
inverse probability of treatment weighted hazard ratios. Because of the recurrent nature of the 
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events of interest, the utilization of the original Cox proportional hazards model is limited due to 
the independence assumption. Because of this assumption the original model is only appropriate 
for modeling time to the first event. The PWP model analyzes ordered multiple events by 
stratifying based on the number of prior events in the follow-up period.101 For our study 
question, the total time model was fitted to assess the effect of all prior/past year depression for 
each ordered event since entry into the risk set (OUD diagnosis). Robust standard errors were 
also applied to account for clustering because of multiple encounters per patient.102 Cumulative 
hazard plots were used to visually display the cumulative hazard function for each event over 
time for each exposure group. 
Sensitivity analyses. A number of sensitivity analyses were completed to assess the 
sensitivity of results to lack of information about possible history of OUD and other factors 
before the original diagnosis in the Geisinger system and the inability to confirm temporal 
pattern of diagnoses. For these sensitivity analyses we created two additional sets of IPTWs that 
excluded 1) mental health diagnoses, other than depression and 2) mental health and substance 
use disorders, other than depression and OUD. Therefore, these sets of IPTWs were limited to 
covariates likely not impacted by depression. We also ran a number of models to assess 
differences in hazard ratios for each outcome. First to account for small risk sets toward the end 
of the observation period, we truncated follow-up time to 10 years after first OUD diagnosis. 
Second, because persons with the OUD without prior/past year depression group could develop 
and receive a depression diagnosis following their first OUD diagnosis, we conducted models 
excluding depression episodes following first OUD diagnosis in the OUD without prior 
depression exposure group, therefore setting the exit date to date of first depression diagnosis or 
date of last GHS encounter. By excluding these depression episodes, the OUD without 
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depression group was limited people who did not have any (prior or following) depression codes 




 Sample characteristics of persons with any prior depression (43.6%), past year depression 
(17.0%) and no depression prior to first opioid use disorder diagnosis (56.4%) are presented in 
Table 3.1. There were a number of differences between groups. Patients with OUD and prior 
depression were more likely to female. Patients with OUD and prior depression were also more 
likely to have the following prior diagnoses: mental health and substance use disorders, medical 
diagnoses (diabetes, hypertension, COPD and/or asthma), and chronic pain (Table 3.1). 
Risk of health service utilization outcome by OUD+ Prior DEP 
 Across all patients, there were a total of 1,225 emergency department encounters and 515 
inpatient encounters that occurred during the follow-up period. 73.2% of emergency department 
encounters (n=897) and 28.5% of inpatient encounters (n=147) included a mental illness or 
substance use disorder code. Suicide-related encounters, including encounters for suicidal 
ideation and attempt, and overdose, were less prevalent. Across time, 56 encounters included a 
suicide attempt or ideation code and 56 encounters included an overdose code. The frequency of 
healthcare encounters at the patient level are presented in Table 3.2. 
 Table 3.3 presents incidence rates, and crude and weighted hazard ratios for each 
healthcare encounter. The weighted hazard of suicide ED encounters was significantly higher 
among persons with any prior or past year depression compared to those without prior depression 
(any prior depression hazard ratio [HR]=2.80, 95% confidence interval [CI]=1.35-5.80; past year 
depression HR=11.93, CI=1.56, 91.04). This was also the case with substance use-related ED 
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encounters (any prior depression HR=1.59, CI=1.04-2.44; past year depression HR=1.76, 
CI=1.11, 2.08). The weighted hazard of an ED encounter including a mental health or substance 
use disorder code was significantly higher among those with past year depression compared to 
those without prior depression (HR=1.70, CI=1.07-2.69). To display these selected results 
graphically, the weighted cumulative hazard plots are displayed in Supplemental Figure 3.1. 
Sensitivity analyses results 
 The analyses with IPTW that excluded prior/past year mental health or substance use 
disorder diagnoses changed slightly. All HRs were in the same direction but statistical 
significance was not met for all. Weighted results did not change significantly when follow-up 
time was truncated to 10 years post first OUD diagnosis. However, after excluding depression 
episodes post OUD diagnosis among patients without a prior depression diagnosis, the weighted 
HRs for MI inpatient encounters and any overdose encounter became statistically significant, and 
the weighted HR for MI ED encounters was no longer statistically significant. For past year 
depression, results were similar. The changes for any prior depression may suggest that we are 
underestimating the effect of depression because we included persons with the OUD with prior 
depression group who received a depression diagnosis following their first OUD diagnosis. 
3.4 Discussion 
 
 The present study examined the association between opioid use disorder with a prior 
depression diagnosis and risk of utilization of the emergency department and inpatient healthcare 
services for mental health and substance use disorders, as well as overdose- and suicide- related 
reasons within the Geisinger Health System in Pennsylvania. We found that a prior depression 
diagnosis was associated with increased risk of emergency department visits that included a 
substance use diagnosis or suicide ideation or attempt code, and/or other mental health and 
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substance use disorder codes. Our results align with previous research suggesting that persons 
with co-occurring substance use and mental health disorders utilize emergency services at greater 
frequency30,99 and that psychiatric comorbidity may influence increased risk of overdose.24–27 
This study uniquely contributes to our understanding of the association between depression 
diagnosis and particular types of emergency department visits. The results suggest that assessing 
and treating depression could be an important factor in reducing later risk of overdose, as well as 
emergency department use among people with opioid use disorder. 
 We found that persons with OUD and any prior or past year depression had a higher rate 
of emergency department visits that included a substance use code not related to opioids. Of this 
sample of adults, 89% of those with both OUD and any prior depression and 92% of those with a 
past year depression code had a prior substance use disorder code that was not opioid use 
disorder in their health records. This is similar to results from nationally represented data. A 
study utilizing the National Survey on Drug Use and Health (NSDUH) from 2002 to 2013 found 
that among persons who used heroin, 96% reported using at least one other substance and 61% 
reported using three or more other substances in the past year. Thirty-five percent also met 
criteria for alcohol use disorder and 25% for cocaine use disorder in the past year.103 
Additionally, fatal overdoses involving stimulants and benzodiazepines have increased in recent 
years,64 with the majority of these overdoses also involving an opioid.104 While we know that the 
use of other substances is not uncommon among persons who use opioids, the role of depression 
in this association is less well understood. Future research should continue to assess the specific 
contribution of depression to the prevalence and severity of other co-occurring substance use 
disorders and to the heightened risk of overdose in these individuals. 
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 Prior depression among patients with OUD was also associated with increased hazard of 
emergency department visits with a suicide attempt or ideation code, and while not statistically 
significant was positively associated with encounters that involved an overdose, whether 
involving opioids or not. While not surprising given the existing research that has found an 
association between depression, and suicide and overdose,24,28 this finding suggests that co-
occurring depression is associated with these adverse outcomes among the vulnerable group of 
individuals with OUD. The potential link between suicide and overdose is an important one to 
consider. Although classification challenges exist,62,105 national trends depict an increase in rates 
of both suicide and unintentional overdose over the past two decades64,106 and it is estimated that 
between 21-33% of overdose deaths may be intentional.28,62,63 Persons with OUD have increased 
risk of suicide, particularly after experiencing a non-fatal overdose.107 Further, the use of 
prescription opioids could be motivated by unmet treatment need for depression, as demonstrated 
by a qualitative study that interviewed relatives or friends of persons who died from an overdose 
involving prescription opioids.63 In the US, 55% of adults with a substance use disorder and co-
occurring major depressive episodes receive treatment for depression,31 and specific to the use of 
antidepressants to treat depression, challenges with treatment continuation exist with less than 
30% of adults continuing antidepressant treatment for longer than three months.108 While having 
an antidepressant prescription at least once during the study period was relatively common in our 
study sample, this does not necessarily indicate continuous treatment and also does not capture 
potential participation in other forms of treatment for depression. Future research is needed to 
understand the impact of treatment for depression, including continuity of antidepressant use, on 
suicide and overdose outcomes among this population of adults with co-occurring opioid use 
disorder and depression. These results also suggests the importance of ensuring suicide 
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prevention is integrated into treatment protocols. Overall emphasis on managing mental health 
disorders, particularly depression, in this population and acknowledging the role of depression in 
developing prevention initiatives for opioid overdose and suicide is critical. 
Limitations 
Along with notable strengths of using EHR data to assess our study question, including 
the ability to examine healthcare utilization over time, there are a number of limitations that need 
to be recognized. First, EHR diagnoses are based on health care providers’ recorded ICD codes. 
Clinicians vary widely with regard to the accuracy of their recorded diagnoses. Second, while 
throughout the text we refer to the first date of opioid use disorder, this denotes to the first opioid 
use disorder code within the Geisinger Health System. We cannot conclude that this was a 
person’s first ever diagnosis and we also cannot assume that a person did not have OUD prior to 
this date, as they could have had an undiagnosed disorder or a diagnosis not included in the 
Geisinger EHR. Additionally, differences in observation time prior to first OUD diagnosis could 
impact likelihood of receiving diagnoses because of differences in contact with the health 
system. While some of this variation could be accounted for by including age in the propensity 
score model, as well as limiting to past year diagnoses; we will account for this in future planned 
analyses. Also, because of how our exposure groups were defined, patients in the OUD without 
prior depression group could have received a depression diagnosis at a later date. Our choice of 
using prior depression as the exposure was done to avoid the possibility of OUD leading to the 
first diagnosis of depression. Our sample size and number of events were also relatively small 
and follow-up time was relatively short, which could have limited statistical power and therefore 
influence the ability to reach statistical significance for some of the healthcare service outcomes. 
Lastly, the study sample includes almost exclusively white non-Hispanic patients receiving 
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healthcare in rural Pennsylvania, which may limit generalizability to more racially diverse and 
urban populations. 
Conclusions 
 Because of the high comorbidity between opioid use disorder and depression,16 and 
recent increases in opioid related-emergency department and inpatient hospitalizations,5 it is 
important to understand the potential role of depression in the use of these healthcare services, as 
well as the adverse outcomes associated with this comorbidity including suicide and overdose. 
The influence of depression comorbidity is complex and warrants further exploration. Despite 
this complexity, it is clear that management of depression and incorporating mental health 
services into medical care and OUD treatment, as well as overdose prevention efforts is needed.
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Table 3.1 Sample characteristics by depression exposure group (N=613) 
 OUD wo prior 
DEP (n=346) 
OUD w prior 
DEP (n=267) 
OUD w past year 
DEP (n=104) 
Unadjusted Odds 
Ratio (95% CI)a 
Unadjusted Odds 
Ratio (95% CI)b 
 n (%) n (%) n (%)   
Sex      
  Female 140 (40.5) 161 (60.3) 59 (56.7) 1.00 1.00 
  Male 206 (59.5) 106 (39.7) 45 (43.3) 0.45 (0.32, 0.62) 0.52 (0.33, 0.81) 
Age groupc      
  18-29 131 (37.9) 92 (34.5) 35 (33.7) 1.00 1.00 
  30-39 125 (36.1) 98 (36.7) 41 (39.4) 1.12 (0.77, 1.63) 1.23 (0.73, 2.05) 
  40-49 55 (15.9) 40 (15.0) 15 (14.4) 1.04 (0.64, 1.68) 1.02 (0.52, 2.02) 
  50+ 35 (10.1) 37 (13.9) 13 (12.5) 1.51 (0.88, 2.57) 1.39 (0.66, 2.91) 
Ethnicityd      
  Hispanic 4 (1.2) 5 (1.9) 3 (2.9) 1.00 1.00 
  Non-Hispanic 341 (98.8) 261 (98.1) 101 (97.1) 0.61 (0.16, 2.30) 0.39 (0.09,1.79) 
Race      
  Non-White 2 (0.6) 1 (0.4) 0 (0.0) 1.00 1.00 
  White 344 (99.4) 266 (99.6) 104 (100.0) 1.55 (0.14, 17.15) 1.00 
      
Prior MH dx 127 (36.7) 216 (80.9) 94 (90.4) 7.30 (5.02, 10.63) 16.21 (8.15, 32.24) 
Prior SU dx 222 (64.2) 238 (89.1) 96 (92.3) 4.58 (2.94, 7.14) 6.70 (3.15, 14.25) 
Prior Med dxe 100 (28.9) 127 (47.6) 54 (51.9) 2.23 (1.60, 3.12) 2.66 (1.69, 4.16) 
Prior HIV or Hepatitis C dx 29 (8.4) 34 (12.7) 12 (11.5) 1.60 (0.94, 2.69) 1.43 (0.70, 2.90) 
Prior Chronic Pain dx 65 (18.8) 77 (28.8) 30 (28.9) 1.75 (1.20, 2.56) 1.75 (1.06, 2.90) 
Prior Buprenorphine medicationf 167 (50.5) 134 (50.8) 46 (45.1) 1.01 (0.73, 1.40) 0.81 (0.52, 1.26) 
a Comparing any prior depression to no prior depression 
b Comparing any past year depression to no prior depression 
c At the time of first OUD diagnosis 
d Missing 2 (sample size 611; 449) 
e Includes hypertensive disease, diabetes mellitus, and other disorders of the airway (i.e. COPD and asthma) 







Table 3.2 Frequency of each healthcare service outcome after first OUD diagnosis by depression exposure group (N=608) 
 OUD wo prior 
DEP (n=341) 
OUD w prior 
DEP (n=267) 
OUD w past year 
DEP (n=104) 
Unadjusted relative 
risk ratio (RRR)a 
(95% CI) 
Unadjusted relative 
risk ratio (RRR)b 
(95% CI) 
Health service outcome n (%) n (%) n (%)   
Emergency Department Encounters     
  Zero 183 (53.7) 147 (55.1) 47 (45.2) 1.00 1.00 
  One 52 (15.3) 43 (16.1) 20 (19.2) 1.03 (0.65, 1.63) 1.49 (0.82, 2.75) 
  Two or more 106 (31.1) 77 (28.8) 37 (35.6) 0.90 (0.63, 1.30) 1.36 (0.83, 2.22) 
Suicide-related      
  Zero 327 (95.9) 253 (94.8) 98  (94.2) 1.00 1.00 
  One 12 (3.5) 7 (2.6) 4 (3.9) 0.75 (0.29, 1.94) 1.11 (0.35, 2.53) 
  Two or more 2 (0.6) 7 (2.6) 2 (1.9) 4.52 (0.93, 22.0) 3.34 (0.46, 24.00) 
Overdose-related      
  Zero 323 (94.7) 260 (97.4) 101 (97.1) 1.00 1.00 
  One 14 (4.1) 5 (1.9) 2 (1.9) 0.44 (0.16, 1.25) 0.46 (0.10, 2.04) 
  Two or more 4 (1.2) 2 (0.6) 1 (1.0) 0.62 (0.11, 3.42) 0.80 (0.09, 7.23) 
MH dx-relatedc      
  Zero 276 (80.9) 192 (71.9) 64 (61.5) 1.00 1.00 
  One 29 (8.5) 36 (13.5) 22 (21.2) 1.78 (1.06, 3.01) 3.27 (1.76, 6.06) 
  Two or more 36 (10.6) 39 (14.6) 18 (17.3) 1.56 (0.95, 2.54) 2.16 (1.15, 4.04) 
SU dx-related      
  Zero 210 (61.6) 170 (63.7) 58 (55.8) 1.00 1.00 
  One 55 (16.1) 36 (13.5) 16 (15.4) 0.81 (0.51, 1.29) 1.05 (0.56, 1.97) 
  Two or more 76 (22.3) 61 (22.9) 30 (28.9) 0.99 (0.67, 1.47) 1.43 (0.86, 2.39) 
MH or SU dx-relatedc      
  Zero 204 (59.8) 165 (61.8) 55 (52.9) 1.00 1.00 
  One 54 (15.8) 37 (13.9) 16 (15.4) 0.85 (0.53, 1.35) 1.10 (0.58, 2.07) 
  Two or more 83 (24.3) 65 (24.3) 33 (31.7) 0.97 (0.66, 1.42) 1.47 (0.89, 2.43) 
Inpatient Encounters      
  Zero 226 (66.3) 170 (63.7) 57 (54.8) 1.00 1.00 
  One 52 (15.3) 41 (15.4) 19 (18.3) 1.04 (0.66,1.65) 1.45 (0.79, 2.64) 
  Two or more 63 (18.5) 56 (21.0) 28 (26.9) 1.18 (0.78, 1.78) 1.76 (1.04, 3.00) 
MH dx-relatedc      
  Zero 318 (93.3) 234 (87.6) 88 (84.6) 1.00 1.00 
  One 14 (4.1) 22 (8.2) 7 (6.7) 2.14 (1.07, 4.26) 1.81 (0.71, 4.61) 
 48 
  Two or more 9 (2.6) 11 (4.1) 9 (8.7) 1.66 (0.68, 4.07) 3.61 (1.39, 9.38) 
SU dx-related      
  Zero 304 (89.2) 232 (86.9) 84 (80.8) 1.00 1.00 
  One 25 (7.3)) 22 (8.2) 9 (8.7) 1.15 (0.63, 2.10) 1.30 (0.59, 2.90) 
  Two or more 12 (3.5) 13 (4.9) 11 (10.6) 1.42 (0.64, 3.17) 3.32 (1.41, 7.79) 
MH or SU dx-relatedc      
  Zero 296 (86.8) 223 (83.5) 82 (78.9) 1.00 1.00 
  One 30 (8.8) 26 (9.7) 10 (9.6) 1.15 (0.66, 2.00) 1.20 (0.56, 2.56) 
  Two or more 15 (4.4) 18 (6.7) 12 (11.5) 1.59 (0.79, 2.23) 2.89 (1.30, 6.41) 
All Overdose-Related Encounters     
  Zero 318 (93.3) 251 (94.0) 98 (94.2) 1.00 1.00 
  One 15 (4.4) 12 (4.5) 5 (4.8) 1.01 (0.47, 2.20) 1.08 (0.38, 3.05) 
  Two or more 8 (2.4) 4 (1.5) 1 (1.0) 0.63 (0.19, 2.13) 0.41 (0.05, 3.28) 
All Suicide-Related Encounters     
  Zero 325 (95.3) 253 (94.8) 98 (94.2) 1.00 1.00 
  One 13 (3.8) 7 (2.6) 4 (3.9) 0.69 (0.27, 1.76) 1.02 (0.33, 3.20) 
  Two or more 3 (0.9) 7 (2.6) 2 (1.9) 3.00 (0.77, 11.71) 2.21 (0.36, 12.42) 
a Comparing any prior depression to no prior depression 
b Comparing any past year depression to no prior depression 















Table 3.3 Healthcare encounters and hazard ratios with 95% confidence intervals (CI) for comparing incidence of each type of encounter between adults 
with OUD without prior depression (reference) and OUD with any prior/past year depression 
a Cox proportional hazards model: the Prentice, Williams and Peterson (PWP) used to estimate crude and stabilized IPTW hazard ratios 
b Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered and/or dispensed) 
c Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year SUD dx, past year 
Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered and/or dispensed) 
d Doubly robust with sex, mental health diagnosis other than depression in year prior to first OUD diagnosis, substance use diagnosis other than OUD in year prior to 
first OUD dx and buprenorphine prescription in year prior to first OUD dx included in both the propensity score weight and regression model 
e Includes depression 
 
 





rate per 1000 
person-years 
Crude Hazard 








rate per 1000 
person-years 
Crude Hazard 




ED encounters         
  All 1225 2.88 1.73 [1.20, 2.49] 1.21 [0.81, 1.80] 937 2.87 2.26 [1.41, 3.63] 1.40 [0.87, 2.25] 
Reason for ED encounter        
  Overdose 34 0.08 1.26 [0.39, 4.11] 1.88 [0.67, 5.28] 28 0.09 0.78 [0.26,2.29] 1.24 [0.05, 34.04] 
  Suicide 45 0.11 2.94 [1.43, 6.03] 2.80 [1.35, 5.80] 29 0.09 8.27 [1.25, 54.87] 11.93 [1.56, 91.04] 
  Mental illness (MI)e 422 0.99 1.62 [0.92, 2.84] 1.13 [0.68, 1.88] 304 0.93 2.14 [1.23,3.72] 1.47 [0.94, 2.31] 
  Substance use (SU) 798 1.88 2.14 [1.41, 3.23] 1.59 [1.04, 2.44] 599 1.84 2.88 [1.80,4.59] 1.76 [1.11, 2.80] 
  MI or SUe 897 2.11 1.95 [1.29, 2.95] 1.41 [0.88, 2.25] 677 2.07 2.69 [1.72,4.20] 1.70 [1.07, 2.69] 
Inpatient encounters         
  All 515 1.21 1.42 [0.72, 2.77] 1.39 [0.72, 2.71] 402 1.23 1.11 [0.43, 2.87] 0.49 [0.23, 1.04] 
Reason for inpatient encounter        
  Mental illness (MI)e 92 0.22 2.11 [0.61, 7.27] 1.64 [0.49, 5.47] 73 0.22 1.26 [0.32, 4.93] 0.61 [0.23, 1.59] 
  Substance use (SU) 114 0.27 2.08 [0.73, 5.94] 1.62 [0.56, 4.68] 96 0.29 1.69 [0.53,5.40] 0.40 [0.10, 1.68] 
  MI or SUe 147 0.35 1.92 [0.68, 5.47] 1.59 [0.57, 4.42] 118 0.36 1.36 [0.40, 4.68] 0.58 [0.20, 1.66] 
Overdose-related         
  Any type of    
encounter for 
overdose 
56 0.13 1.94 [0.80, 4.73] 2.27 [0.99, 5.21] 42 0.13 1.41 [0.50, 3.97] 1.65 [0.18, 15.03] 
Suicide-related         
  Any type of   
encounter for suicide 
56 0.13 1.77 [0.83, 3.81] 1.73 [0.80, 3.72] 38 0.12 8.27 [1.25, 54.87] 3.39 [0.47, 24.40] 
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Supplemental Table 3.1 ICD 9 and ICD 10 codes used to define diagnoses 
Diagnosis categories Diagnosis Included 
Mental health and Substance use   
Opioid use disorder ICD9: 304, 304.0, 304.00-.02, 305.5, 305.50-.52 
ICD10: F11, F11.1, F11.10, F11.12, F11.120-.122, F11.129, F11.14, 
F11.15, F11.150-.151, F11.159, F11.18, F11.181-.182, F11.188, F11.19, 
F11.2, F11.20, F11.22, F11.220-.222", F11.229, F11.23-.25, F11.250-
.251, F11.259, F11.28, F11.281-.282, F11.288, F11.29, F11.9, F11.90, 
F11.92, F11.920-.922, F11.929, F11.93-.95, F11.950-.951, F11.959, 
F11.98, F11.981-.982, F11.988, F11.99 
Depressive disorders ICD9: 296.2*, 296.3*, 300.4*, 311 
ICD10: F32*, F33*, F34.1 
Other substance use disorder ICD9: 303*, 304.1*, 304.2*, 304.3*, 304.4*, 304.5*, 304.6*, 304.8*, 
304.9*, 305.0*, 305.1*,305.2*, 305.3*, 305.4*, 305.6*, 305.7*, 305.9* 
ICD10: F10*, F12*-F19*, F55* 
Other mental health disorder  ICD9: 290*-296*, 297*-299*, 300*, 301*, 302*, 308*, 309* 
ICD10: F01*-F09*, F20*-F25*, F28*-F29*,  F31*, F34*, F39, F40*, 
F41.0, F41.1, F41.3, F41.8, F41.9, F42*-F45*, F48*, F50*-F52*, F54*, 
F59*, F60*, F63*-F69*, F99* 
Suicide attempt ICD9: E950*-E958* 
ICD10: T14.91*, X71*-X83* 
Suicide ideation ICD9: V62.84 
ICD10: R45.851 
Overdose  
Opioid overdose ICD9: 965, 965.0, 965.01, 965.09, E850.0, E850.2 
ICD10: T40.0X1*, T40.0X2*, T40.0X4*, T40.1-.4*, T40.6* 
Other drug overdose  ICD9: 965.1, 965.4, 965.5, 965.6*, 965.7-.9, 967*, 968*, 969*, 969.4, 
970*, 970.81 980*, 981, 982*, E850.3-.9, E851, E852*, E853*, E854*, 
E855.1, E858.8-.9, E860*, E862*, E980*, E980.0-.5 
ICD10: T39.011*, T39.012*, T39.014*, T39.091*, T39.092*, T39.094*, 
T39.4X1*, T39.4X2*, T39.4X4*, T39.8X1*, T39.8X2*, T39.8X4*, 
T39.91*, T39.92*, T39.94*, T40.5X1*, T40.5X2*, T40.5X4*, T40.7X1*, 
T40.7X2*, T40.7X4*, T40.8X1*, T40.8X2*, T40.8X4*, T40.901*, 
T40.902*, T40.904*, T40.991*, T40.992*, T40.994*, T41.0X1*, 
T41.0X2*, T41.0X4*, T41.1X1*, T41.1X2*, T41.1X4*, T41.201*, 
T41.202*, T41.204*, T41.291*, T41.292*, T41.294*, T41.3X1*, 
T41.3X2*, T41.3X4*, T41.41*, T41.42*, T41.44*, T42.3X1*, T42.3X2*, 
T42.3X4*, T42.4X1*, T42.4X2*, T42.4X4*, T43.601*, T43.602*, 
T43.604*, T43.621*, T43.622*, T43.624*, T43.631*, T43.632*, 
T43.634*, T43.641*, T43.642*, T43.644*, T43.691*, T43.692*, 
T43.694*, T43.8X1*, T43.8X2*, T43.8X4*, T43.91*, T43.92*, T43.94* 
Other medical   
Chronic pain  ICD9: 338.2*, 338.4,  
ICD10: G89.2*, G89.4 
HIV and Hepatitis C ICD9: 042, 070.41, 070.44, 070.51, 070.54, 070.71 
ICD10: B20, B17.1*, B18.2, B19.2* 
Other (includes hypertensive disease, 
diabetes mellitus, disorders of the 
airway-COPD and asthma) 
ICD9: 401*-405*, 205*, 490*-496* 







Supplemental Table 3.2 Proportions for each covariate and standardized differences comparing opioid use disorder without any prior 
depression and opioid use disorder with any prior depression before and after weighting for all prior diagnoses limited to patients with at 
least a year of observation prior to first opioid use disorder diagnosis  
  Crude (Unweighted) Weighted (stabilized)c 




















Age Category         
  18-29 37.9 34.5 3.4 -0.071 37.5 37.8 0.3 0.006 
  30-39 36.1 36.7 0.6 0.012 35.9 35.4 0.5 -0.009 
  40-49 15.9 15.0 0.9 -0.025 15.0 16.0 1.0 0.028 
  50+ 10.1 13.9 3.8 0.115 11.7 10.8 0.9 -0.027 
Male sex 59.5 39.7 19.8 -0.404 49.0 48.2 0.8 -0.017 
Non-Hispanic 
Ethnicity 
98.8 98.1 0.7 -0.059 98.0 97.6 0.4 -0.031 
White race 99.4 99.6 0.2 0.030 99.5 99.6 0.1 0.013 
Prior MH dx 36.7 80.9 44.2 1.003 57.5 58.3 0.8 0.016 
Prior SU dxa 64.2 89.1 24.9 0.617 76.1 77.3 1.2 0.030 
Prior Med dxa 28.9 47.6 18.7 0.391 37.2 37.9 0.7 0.015 
Prior HIV/ Hep C dxa 8.4 12.7 4.3 0.142 11.8 11.4 0.4 -0.013 
Prior chronic pain dxa 18.8 28.8 10.0 0.237 24.9 25.8 0.9 0.021 
Prior bup med a,b 50.5 50.8 0.3 0.006 50.4 53.8 3.4 0.068 
a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Includes past ordered or dispensed buprenorphine medications; Unweighted sample sizes: OUD without prior DEP n=331, OUD with prior DEP 
n=264; Weighted sample sizes: OUD without prior DEP n=330, OUD with prior DEP n=263 
c Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior 











Supplemental Table 3.3 Proportions for each covariate and standardized differences comparing opioid use disorder without past year 
depression and opioid use disorder with past year depression before and after weighting for all past year diagnoses limited to patients with at 
least a year of observation prior to first opioid use disorder diagnosis  
a OUD without past year DEP= no depression OR depression on/after first OUD dx (n=346); OUD with past year DEP =had at least one depression code within 
year prior to first OUD dx (n=104); patients that had a depression code more than a year prior to first OUD dx and did not have another were excluded (n=163) 
b The definition of all of these DO NOT include the day of OUD dx (e.g. within 1 year prior to first OUD dx date) 
c Includes past ordered or dispensed buprenorphine medications; Unweighted sample sizes: OUD without prior DEP n=331, OUD with prior DEP 
n=102; Weighted sample sizes: OUD without prior DEP n=328, OUD with prior DEP n=102 
d Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior year MI dx, prior year SUD dx, 









  Crude (Unweighted) Weighted (stabilized)d 
  OUD wo past 
year DEP 
(n=346) 







OUD wo past 
year DEP 
(n=328) 







Age Category         
  18-29 37.9 33.7 4.2 -0.088 35.8 40.4 4.6 0.096 
  30-39 36.1 39.4 3.3 0.068 39.1 38.9 0.2 -0.005 
  40-49 15.9 14.4 1.5 -0.041 14.2 7.9 6.3 -0.175 
  50+ 10.1 12.5 2.4 0.075 10.8 12.8 2.0 0.061 
Male sex 59.5 43.3 16.2 -0.329 53.9 39.3 14.6 -0.296 
Non-Hispanic Ethnicity 98.8 97.1 1.7 -0.122 98.6 98.3 0.3 -0.023 
White race 99.4 100.0 0.6 0.108 100.0 100.0 0.0 0.000 
Prior year MH dxb 14.5 74.0 59.5 1.494 30.8 36.9 6.1 0.154 
Prior year SU dxb 28.9 73.1 44.2 0.982 41.9 48.4 6.5 0.145 
Prior year Med dxb 12.1 40.4 28.3 0.675 20.9 24.8 3.9 0.095 
Prior year HIV/ Hep C dxb 1.4 5.8 4.4 0.233 1.9 3.2 1.3 0.070 
Prior year chronic pain dxb 6.1 21.2 15.1 0.449 9.3 10.9 1.6 0.049 
Prior year bup medb,c 46.5 39.2 7.3 -0.148 44.0 38.1 5.9 -0.120 
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Supplemental Figure 3.1 Weighted cumulative hazard plots for A) all prior depression B) past year depression  
 
A) All prior depression 
 
















B) Past year depression 
 
















Chapter 3 Appendices 
 
3.1 Frequency of each healthcare service outcome before and after first OUD diagnosis 
 After OUD dxa Before OUD dxa Total 
Total number of encounters 21,058 31,125 52,183 
Emergency Department Encounters    
  All 1,225 3,976 5,201 
  Overdose-related 34 77 111 
  Suicide-related 45 85 130 
  MH dx-related 422 628 1,050 
  SU dx-related 798 1,204 2,002 
  MH or SU dx-related 897 1,429 2,326 
Inpatient Encounters    
  All 515 975 1,490 
  MH dx-related 92 184 276 
  SU dx-related 114 219 333 
  MH or SU dx-related 147 295 442 
All Overdose-Related Encounters 56 111 167 
All Suicide-Related Encounters 56 110 166 
a First OUD dx in EHR 
 
3.2 Comparing days to exit: 1) from first GHS encounter date; 2) from first OUD dx date 
 Mean Days to Exit 
(SD) 
Range 
From first encounter 5669.3 (1792.7) 530, 8425 
From OUD origin 872.4 (917.4) 0, 7724 
 
 
3.3 Differences in length of observation prior to first OUD diagnosis between depression groups 
 No prior depression All prior depression  Past year depression 
 Mean (SD) Range Mean (SD) Range Mean (SD) Range 
Days to first OUD dx 2984.2 (2357.2) 0,8127 4674.9 (1968.8) 34,8328 4272.2 (2182.1) 34,8216 





3.4 Sample characteristics by depression exposure group- All prior depression and no exclusion  
based on observation length between first GHS encounter and first OUD diagnosis 
 OUD wo prior 
DEP (n=447) 
OUD w prior 
DEP (n=274) 
Unadjusted Odds 
Ratio (95% CI) 
 n (%) n (%)  
Sex    
  Female 179 (40.0) 164 (59.9) 1.00 
  Male 268 (60.0) 110 (40.2) 0.45 (0.33, 0.61) 
Age groupa    
  18-29 169 (37.8) 95 (36.7) 1.00 
  30-39 165 (36.9) 95 (34.7) 1.08 (0.76, 1.54) 
  40-49 69 (15.4) 42 (15.3) 1.08 (0.68, 1.71) 
  50+ 44 (9.8) 37 (13.5) 1.50 (0.90, 2.48) 
Ethnicity    
  Hispanic 13 (2.9) 5 (1.8) 1.00 
  Non-Hispanic 433 (97.1) 268 (98.2) 1.61 (0.57, 4.56) 
Race    
  Non-White 6 (1.3) 1 (0.4) 1.00 
  White 441 (98.7) 273 (99.6) 3.71 (0.44, 31.01) 
    
Prior MH dx 136 (30.4) 219 (79.9) 9.12 (6.37, 13.02) 
Prior SU dx 238 (53.2) 242 (88.3) 6.64 (4.39, 10.04) 
Prior Med dxb 106 (23.7) 128 (46.7) 2.82 (2.04, 3.89) 
Prior HIV or Hepatitis C dx 30 (6.7) 34 (12.4) 1.97 (1.18, 3.30) 
Prior Chronic Pain dx 65 (14.5) 78 (28.5) 2.34 (1.61, 3.39) 
Prior Buprenorphine medicationc 215 (50.7) 136 (50.2) 0.98 (0.72, 1.33) 
a At the time of first OUD diagnosis 
b Includes hypertensive disease, diabetes mellitus, and other disorders of the airway (i.e. COPD and asthma) 










3.5 Frequency of each healthcare service outcome by depression exposure group-  
All prior depression and no exclusion based on observation length between first  
GHS encounter and first OUD diagnosis 
 OUD wo prior 
DEP (n=447) 
OUD w prior 
DEP (n=274) 
Health service outcome n (%) n (%) 
Emergency Department Encountersa   
  All 190 (42.5) 122 (44.5) 
One 66 (34.7) 45 (36.9) 
Two or more 124 (65.3) 77 (63.1) 
  Overdose-related 20 (4.5) 7 (2.6) 
One 15 (75.0) 5 (71.4) 
Two or more 5 (25.0) 2 (28.6) 
  Suicide-related 16 (3.6) 14 (5.1) 
One 14 (87.5) 7 (50.0) 
Two or more 2 (12.5) 7 (50.0) 
  MH dx-relatedb 77(17.2) 75 (27.4) 
One 37 (48.1) 36 (48.0) 
Two or more 40 (51.9) 39 (52.0) 
  SU dx-related 158 (35.3) 97 (35.4) 
One 69 (43.7) 36 (37.1) 
Two or more 89 (56.3) 61 (62.9) 
  MH or SU dx-relatedb 166 (37.1) 102 (37.2) 
One 69 (41.6) 37 (36.3) 
Two or more 97 (58.4) 65 (63.7) 
Inpatient Encountersa   
  All 131 (29.3) 98 (35.8) 
One 57 (43.5) 42 (42.9) 
Two or more 74 (56.5) 56 (57.1) 
  MH dx-relatedb 24 (5.4) 33 (12.0) 
One 15 (62.5) 22 (66.7) 
Two or more 9 (37.5) 11 (33.3) 
  SU dx-related 42 (9.4) 35 (12.8) 
One 29 (69.0) 22 (62.9) 
Two or more 13 (31.0) 13 (37.1) 
  MH or SU dx-relatedb 50 (11.2) 44 (16.1) 
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One 33 (66.0) 26 (59.1) 
Two or more 17 (34.0) 18 (40.9) 
All Overdose-Related Encountersa 26 (5.8) 16 (5.8) 
One 17 (65.4) 12 (75.0) 
Two or more 9 (34.6) 4 (25.0) 
All Suicide-Related Encountersa 18 (4.0) 14 (5.1) 
One 15 (83.3) 7 (50.0) 































3.6  Sample characteristics by the following depression groups: 1) OUD only; 2) OUD+ Prior DEP; 3) OUD + Post DEP (N=721)-  
No exclusion based on observation length between first GHS encounter and first OUD diagnosis 
 OUD only  
(n=367) 
OUD + Prior DEP 
(n=274) 
OUD + Post DEP 
(n=80)a 
 n (%) n (%) n (%) 
Sex    
  Female 144 (39.2) 164 (59.9) 35 (43.8) 
  Male 223 (60.8) 110 (40.2) 45 (56.3) 
Age groupb    
  18-29 133 (36.2) 95 (36.7) 36 (45.0) 
  30-39 143 (39.0) 95 (34.7) 22 (27.5) 
  40-49 54 (14.7) 42 (15.3) 15 (18.8) 
  50+ 37 (10.9) 37 (13.5) 7 (8.7) 
Ethnicity    
  Hispanic 12 (3.3) 5 (1.8) 1 (1.3) 
  Non-Hispanic 354 (96.7) 268 (98.2) 79 (98.7) 
Race    
  Non-White 4 (1.1) 1 (0.4) 2 (2.5) 
  White 363 (98.9) 273 (99.6) 78 (97.5) 
    
Prior MH dx 103 (28.1) 219 (79.9) 33 (41.3) 
Prior SU dx 188 (51.2) 242 (88.3) 50 (62.5) 
Prior Med dxc 81 (22.1) 128 (46.7) 25 (31.3) 
Prior HIV or Hepatitis C dx 26 (7.1) 34 (12.4) 4 (5.0) 
Prior Chronic Pain dx 56 (15.3) 78 (28.5) 9 (11.3) 
Prior Buprenorphine medicationd 186 (53.8) 136 (50.2) 29 (37.2) 
a 23 patients had first date of OUD and first date of DEP on the same day 
b At the time of first OUD diagnosis 
c Includes hypertensive disease, diabetes mellitus, and other disorders of the airway (i.e. COPD and asthma) 









3.7 Healthcare encounters and hazard ratios with 95% confidence intervals (CI) for comparing incidence of each type of encounter 
between adults with OUD without prior depression (reference) and OUD with any prior depression- No exclusion based on observation 
length between first GHS encounter and first OUD diagnosis 
 Number of 
events 
Incidence rate per 
1000 person-years 
Crude Hazard 
Ratio [95% CI] 
IPTW adjusted 
Hazard Ratio  
[95% CI]a 
IPTW adjusted 
Hazard Ratio  
[95% CI]b 
IPTW adjusted 
Hazard Ratio  
[95% CI]c 
ED encounters       
  All 1339 2.73 1.98 [1.40, 2.81] 1.41 [0.95, 2.08] 1.41 [0.86, 2.29] 1.66 [1.15, 2.39] 
Reason for ED encounter       
  Overdose 37 0.08 1.26 [0.40, 4.11] 2.02 [0.71, 5.70] 2.12 [0.75, 6.02] 1.85 [0.59, 5.76] 
  Suicide 47 0.10 3.37 [1.66, 6.88] 3.33 [1.58, 7.04] 2.75 [1.41, 5.35] 2.84 [1.39, 5.79] 
  Mental illness (MI)d 444 0.90 1.73 [1.05, 2.86] 1.21 [0.75, 1.96] 1.15 [0.69,1.93] 1.34 [0.82, 2.21] 
  Substance use (SU) 861 1.75 2.25 [1.54, 3.30] 1.68 [1.12, 2.53] 1.57 [0.97, 2.55] 1.83 [1.22, 2.75] 
  MI or SUd 968 1.97 2.05 [1.40, 3.00] 1.49 [0.95, 2.34] 1.32 [0.73, 2.41] 1.64 [1.07, 2.50] 
Inpatient encounters       
  All 549 1.12 1.40 [0.73, 2.66] 1.42 [0.74, 2.72] 1.34 [0.70, 2.58] 1.17 [0.60, 2.28] 
Reason for inpatient 
encounter 
      
  Mental illness (MI)  93 0.19 2.11 [0.61, 7.27] 1.68 [0.50, 5.70] 1.82 [0.53, 6.31] 1.47 [0.41, 5.29] 
  Substance use (SU) 121 0.25 2.00 [0.72, 5.56] 1.57 [0.54, 4.60] 1.63 [0.54, 4.86] 1.49 [0.52, 4.30] 
  MI or SUd 155 0.32 1.89 [0.68, 5.23] 1.58 [0.56, 4.45] 1.64 [0.57, 4.77] 1.43 [0.49, 4.18] 
Overdose-related       
  Any type of encounter for 
overdose 
60 0.12 1.94 [0.80, 4.72] 2.39 [1.04, 5.50] 2.48 [1.09, 5.65] 2.29 [0.95, 5.52] 
Suicide-related       
  Any type of encounter for 
suicide 
58 0.12 2.02 [0.95, 4.28] 2.00 [0.90, 4.44] 1.79 [0.89, 3.63] 1.90 [0.94, 3.82] 
a Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered and/or dispensed) 
b Excludes prior mental health 
c Excludes prior mental health and substance use disorder codes 










3.8 Hazard ratios 1) Truncating follow-up time at 10 years; 2) Excluding depression episodes that occur after OUD dx; 3) Excluding 
depression from MI outcomes for any prior depression 
 Truncated at 10 years Excluding depression episodes post OUD 
 Crude Hazard Ratio 
[95% CI] 
IPTW adjusted Hazard 
Ratio [95% CI] 
Crude Hazard Ratio 
[95% CI] 
IPTW adjusted Hazard 
Ratio [95% CI] 
ED encounters     
  All 1.68 [1.16, 2.44] 1.18 [0.79, 1.76] 1.85 [1.27, 2.68] 1.34 [0.91, 1.96] 
Reason for ED encounter     
  Overdose 1.26 [0.39,4.11] 1.88 [0.67,5.28] 1.35 [0.28, 6.47] 1.85 [0.59, 5.79] 
  Suicide 2.94 [1.43,6.03] 2.80 [1.36, 5.80] 2.90 [1.18, 7.11] 2.34 [0.91, 6.06] 
  Mental illness (MI)a 1.52 [0.85, 2.71] 1.08 [0.64,1.80] 1.42 [0.77, 2.63] 1.17 [0.66, 2.08] 
  Substance use (SU) 2.07 [1.37, 3.14] 1.55 [1.01, 2.38] 2.07 [1.34, 3.19] 1.58 [1.02, 2.46] 
  MI or SUa 1.89 [1.25, 2.85] 1.37 [0.86, 2.19] 1.99 [1.30, 3.04] 1.49 [0.93, 2.39] 
Inpatient encounters     
  All 1.42 [0.72, 2.77] 1.39 [0.72, 2.71] 1.52 [0.88, 2.62] 1.56 [0.87, 2.80] 
Reason for inpatient encounter     
  Mental illness (MI)a 2.11 [0.61, 7.27] 1.64 [0.49, 5.47] 4.59 [1.70, 12.40] 3.53 [1.31, 9.51] 
  Substance use (SU) 2.08 [0.73, 5.94] 1.62 [0.56, 4.68] 2.23 [0.81, 6.13] 1.61 [0.59, 4.37] 
  MI or SUa 1.92 [0.68, 5.47] 1.59 [0.57, 4.42] 2.48 [0.97, 6.34] 1.93 [0.78, 4.79] 
Overdose-related     
  Any type of encounter for overdose 1.94 [0.80, 4.73] 2.27 [0.99, 5.21] 2.31 [0.87, 6.12] 2.56 [1.12, 5.84] 
Suicide-related     
  Any type of encounter for suicide 1.77 [0.83, 3.81] 1.73 [0.80, 3.72] 3.08 [1.20, 7.93] 2.46 [0.94, 6.48] 
b Includes depression 
 
Excluding depression from MI outcomes 
 Crude Hazard Ratio [95% CI] IPTW adjusted Hazard Ratio [95% CI] 
ED encounters   
  All 1.73 [1.20, 2.49] 1.21 [0.81, 1.80] 
Reason for ED encounter   
  Overdose 1.26 [0.39, 4.11] 1.88 [0.67, 5.28] 
  Suicide 2.94 [1.43, 6.03] 2.80 [1.35, 5.80] 
  Mental illness (MI) (excluding dep) 1.19 [0.67, 2.11] 0.93 [0.52, 1.66] 
  Substance use (SU) 2.14 [1.41, 3.23] 1.59 [1.04, 2.44] 
  MI or SU (excluding dep) 1.97 [1.31, 2.96] 1.46 [0.93, 2.31] 
Inpatient encounters   
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  All 1.42 [0.72, 2.77] 1.39 [0.72, 2.71] 
Reason for inpatient encounter   
  Mental illness (MI) (excluding dep) 1.32 [0.33, 5.29] 1.07 [0.29, 3.98] 
  Substance use (SU) 2.08 [0.73, 5.94] 1.62 [0.56, 4.68] 
  MI or SU (excluding dep) 1.83 [0.62, 5.40] 1.50 [0.51, 4.36] 
Overdose-related   
  Any type of encounter for overdose 1.94 [0.80, 4.73] 2.27 [0.99, 5.21] 
Suicide-related   
  Any type of encounter for suicide 1.77 [0.83, 3.81] 1.73 [0.80, 3.72] 
 
 
3.9 Hazard ratios 1) Truncating follow-up time at 10 years; 2) Excluding depression episodes that occur after OUD dx; 3) Excluding 
depression from MI outcomes for past year depression 
 Truncated at 10 years Excluding depression episodes post OUD 
 Crude Hazard Ratio 
[95% CI] 
IPTW adjusted Hazard 
Ratio [95% CI]a 
Crude Hazard Ratio 
[95% CI] 
IPTW adjusted Hazard 
Ratio [95% CI]a 
ED encounters     
  All 2.21 [1.36, 3.58] 1.34 [0.71, 2.54] 2.41 [1.45, 3.93] 1.58 [0.90, 2.78] 
Reason for ED encounter     
  Overdose 0.78 [0.26, 2.29] 2.36 [0.19, 30.08] 0.46 [0.06, 3.33] 0.71 [0.10, 4.92] 
  Suicide 8.27 [1.25, 54.87] 8.17 [0.95, 69.58] 6.04 [0.87, 42.04] 8.08 [1.40, 46.51] 
  Mental illness (MI)b 1.98 [1.10, 3.58] 1.53 [0.95, 2.47] 1.83 [0.94, 3.58] 1.48 [0.90, 2.43] 
  Substance use (SU) 2.78 [1.72, 4.48] 2.13 [1.38, 3.31] 2.71 [1.62, 4.51] 2.12 [1.31, 3.43] 
  MI or SUb 2.59 [1.64, 4.10] 2.06 [1.35, 3.14] 2.69 [1.67, 4.35] 2.22 [1.41, 3.51] 
Inpatient encounters     
  All 1.11 [0.43, 2.87] 0.46 [0.15, 1.40] 1.19 [0.55, 2.60] 0.59 [0.22, 1.57] 
Reason for inpatient encounter     
  Mental illness (MI)b 1.26 [0.32, 4.93] 0.28 [0.05, 1.61] 2.58 [0.97, 6.82] 1.02 [0.26, 4.01] 
  Substance use (SU) 1.69 [0.53, 5.40] 0.42 [0.07, 2.56] 1.79 [0.60, 5.35] 0.49 [0.08, 2.82] 
  MI or SUb 1.36 [0.40, 4.68] 0.35 [0.07, 1.78] 1.72 [0.59, 4.98] 0.51 [0.10, 2.50] 
Overdose-related     
  Any type of encounter for overdose 1.41 [0.50, 3.97] 1.01 [0.16, 6.53] 1.56 [0.48, 5.04] 0.87 [0.09, 7.19] 
Suicide-related     
  Any type of encounter for suicide 8.27 [1.25, 54.87] 7.85 [0.81, 76.21] 6.04 [0.87, 42.04] 8.08 [1.40, 46.51] 
a Regression model includes sex 
b Includes depression 
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Excluding depression from MI outcomesa 
 Crude Hazard Ratio [95% CI] IPTW adjusted Hazard Ratio [95% CI]a 
ED encounters   
  All 2.26 [1.41, 3.63] 1.37 [0.73, 2.58] 
Reason for ED encounter   
  Overdose 0.78 [0.26,2.29] 2.36 [0.19, 30.08] 
  Suicide 8.27 [1.25,54.87] 8.14 [0.95, 69.58] 
  Mental illness (MI) (excluding dep) 1.85 [1.05, 3.25] 1.45 [0.83, 2.54] 
  Substance use (SU) 2.88 [1.80,4.59] 2.21 [1.44, 3.40] 
  MI or SU (excluding dep) 2.66 [1.68, 4.20] 2.08 [1.38, 3.15] 
Inpatient encounters   
  All 1.11 [0.43, 2.87] 0.46 [0.15, 1.40] 
Reason for inpatient encounter   
  Mental illness (MI) (excluding dep) 0.79 [0.18, 3.54] 0.14 [0.03, 0.72] 
  Substance use (SU) 1.69 [0.53,5.40] 0.42 [0.07, 2.56] 
  MI or SU (excluding dep) 1.31 [0.38, 4.50] 0.34 [0.07, 1.75] 
Overdose-related   
  Any type of encounter for overdose 1.41 [0.50, 3.97] 1.01 [0.16, 6.53] 
Suicide-related   
  Any type of encounter for suicide 8.27 [1.25, 54.87] 7.85 [0.81, 76.21] 


















3.10 Healthcare encounters and hazard ratios with 95% confidence intervals (CI) for comparing incidence of each type of encounter between adults with 
OUD without prior depression (reference) and OUD with any prior/past year depression:a  Limited propensity score models 








Hazard Ratio  
[95% CI]b 
IPTW adjusted 





rate per 1000 
person-years 
IPTW adjusted 
Hazard Ratio  
[95% CI]b 
IPTW adjusted 
Hazard Ratio  
[95% CI]c 
ED encounters         
  All 1225 2.88 1.29 [0.81, 2.07] 1.50 [1.03, 2.20] 937 2.87 1.46 [0.82, 2.59] 1.83 [1.16, 2.90] 
Reason for ED 
encounter 
        
  Overdose 34 0.08 1.98 [0.70, 5.63] 1.77 [0.56, 5.58] 28 0.09 1.17 [0.37, 3.66] 0.95 [0.30, 2.97] 
  Suicide 45 0.11 2.39 [1.25, 4.55] 2.57 [1.27, 5.22] 29 0.09 7.52 [0.65, 87.02] 7.35 [0.80, 67.30] 
  Mental illness 
(MI)d 
422 0.99 1.12 [0.66,1.92] 1.31 [0.76, 2.24] 304 0.93 1.29 [0.71, 2.34] 1.64 [0.95, 2.81] 
  Substance use (SU) 798 1.88 1.57 [0.96, 2.55] 1.82 [1.18, 2.79] 599 1.84 2.12 [1.33, 3.39] 2.54 [1.68, 3.85] 
  MI or SUd 897 2.11 1.33 [0.75, 2.39] 1.63 [1.05, 2.55] 677 2.07 1.98 [1.25, 3.14] 2.31 [1.54, 3.46] 
Inpatient encounters         
  All 515 1.21 1.33 [0.69, 2.59] 1.22 [0.62, 2.40] 402 1.23 1.06 [0.42, 2.71] 0.88 [0.30, 2.56] 
Reason for inpatient 
encounter 
        
  Mental illness (MI)  92 0.22 1.79 [0.52, 6.14] 1.54 [0.44, 5.42] 73 0.22 1.08 [0.24, 4.91] 0.82 [0.17, 4.04] 
  Substance use (SU) 114 0.27 1.66 [0.56, 4.94] 1.59 [0.55, 4.60] 96 0.29 1.45 [0.37, 5.66] 1.26 [0.34, 4.67] 
  MI or SUd 147 0.35 1.64 [0.57, 4.75] 1.50 [0.52, 4.36] 118 0.36 1.20 [0.30, 4.89] 1.00 [0.25, 4.03] 
Overdose-related         
  Any type of 
encounter for 
overdose 
56 0.13 2.34 [1.02, 5.37] 2.20 [0.91, 5.53] 42 0.13 1.56 [0.59, 4.10] 1.50 [0.53, 4.18] 
Suicide-related         
  Any type of 
encounter for 
suicide 
56 0.13 1.58 [0.79, 3.17] 1.70 [0.84, 3.44] 38 0.12 7.52 [0.65, 87.02] 7.36 [0.80, 67.30] 
a Limited to patients with at least one year of observation prior to first opioid use disorder diagnosis 
b IPTW excludes prior mental health 
c IPTW excludes prior mental health and substance use disorder codes 






3.11 Healthcare encounters and hazard ratios with 95% confidence intervals (CI) for comparing incidence of each type of encounter 
between adults with OUD without prior depression (reference) and OUD with any prior/past year depression:a  Missing indicator IPTW 
 
a Limited to patients with at least one year of observation prior to first opioid use disorder diagnosis 
b IPTW includes missing data indicator for prior/past year buprenorphine prescriptions 
c Regression model includes sex 






















Hazard Ratio  
[95% CI]b,c 
ED encounters       
  All 1225 2.86 1.16 [0.80, 1.73] 930 2.85 1.29 [0.70, 2.37] 
Reason for ED 
encounter 
      
  Overdose 34 0.09 1.82 [0.73, 4.54] 27 0.08 2.32 [0.18, 29.63] 
  Suicide 45 0.09 2.86 [1.38, 5.93] 29 0.06 8.41 [0.97, 73.16] 
  Mental illnessd 422 1.01 1.14 [0.68,1.88] 303 1.00 1.61 [1.01, 2.55] 
  Substance use 798 1.84 1.45 [0.95, 2.31] 594 1.71 1.87 [1.12, 3.10] 
  MI or SUd 897 2.12 1.33 [0.83, 2.12] 672 2.00 1.84 [1.14, 2.97] 
Inpatient encounters       
  All 515 1.22 1.39 [0.71, 2.70] 398 1.22 0.44 [0.15, 1.34] 
Reason for inpatient 
encounter 
      
  Mental illnessd 92 0.20 1.64 [0.49, 5.47] 73 0.20 0.25 [0.04, 1.40] 
  Substance use  114 0.23 1.59 [0.55, 4.58] 96 0.22 0.35 [0.06, 2.13] 
  MI or SUd 147 0.31 1.56 [0.56, 4.36] 118 0.31 0.31 [0.06, 1.55] 
Overdose-related       
  Any type of encounter 
for overdose 
56 0.15 2.24 [1.01, 4.96] 41 0.13 1.00 [0.15, 6.52] 
Suicide-related       
  Any type of encounter 
for suicide 
56 0.11 1.75 [0.80, 3.82] 38 0.09 8.07 [0.82, 79.04] 
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3.12 Proportions of covariates and standardized differences for all prior depression limited to patients with at least a year of observation prior to first 
OUD diagnosis with a) excluding prior mental illness diagnoses from IPTW; b) excluding prior mental illness and substance use disorder diagnoses 
from IPTW 
 
a. All prior depression: excluding prior mental illness from propensity score model and IPTW 
  Crude (Unweighted) Weighted (stabilized)c 




















Age Category         
  18-29 37.9 34.5 3.4 -0.071 36.9 37.7 0.8 0.018 
  30-39 36.1 36.7 0.6 0.012 36.2 36.8 0.6 0.012 
  40-49 15.9 15.0 0.9 -0.025 15.4 14.7 0.7 -0.020 
  50+ 10.1 13.9 3.8 0.115 11.5 10.7 0.8 -0.022 
Male sex 59.5 39.7 19.8 -0.404 49.1 48.8 0.3 -0.006 
Non-Hispanic 
Ethnicity 
98.8 98.1 0.7 -0.059 97.8 98.2 0.4 0.036 
White race 99.4 99.6 0.2 0.030 99.5 99.6 0.1 0.010 
Prior SU dxa 64.2 89.1 24.9 0.617 76.1 77.5 1.4 0.035 
Prior Med dxa 28.9 47.6 18.7 0.391 38.3 37.9 0.4 -0.008 
Prior HIV/ Hep C dxa 8.4 12.7 4.3 0.142 11.7 11.7 0.0 0.001 
Prior chronic pain dxa 18.8 28.8 10.0 0.237 24.2 24.3 0.1 0.001 
Prior bup med a,b 50.5 50.8 0.3 0.006 50.7 50.4 0.3 -0.005 
  
b. All prior depression: excluding prior mental illness and substance use disorders from propensity score model and IPTW 
  Crude (Unweighted) Weighted (stabilized)c 




















Age Category         
  18-29 37.9 34.5 3.4 -0.071 36.7 36.4 0.3 -0.006 
  30-39 36.1 36.7 0.6 0.012 35.9 36.5 0.6 0.010 
  40-49 15.9 15.0 0.9 -0.025 15.8 15.8 0.0 -0.002 
  50+ 10.1 13.9 3.8 0.115 11.5 11.4 0.1 -0.004 
Male sex 59.5 39.7 19.8 -0.404 49.7 49.9 0.2 0.005 
Non-Hispanic 
Ethnicity 
98.8 98.1 0.7 -0.059 98.1 98.4 0.3 0.020 
White race 99.4 99.6 0.2 0.030 99.5 99.6 0.1 0.013 
Prior Med dxa 28.9 47.6 18.7 0.391 37.9 37.6 0.3 -0.006 
Prior HIV/ Hep C dxa 8.4 12.7 4.3 0.142 11.2 11.2 0.0 -0.000 
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Prior chronic pain dxa 18.8 28.8 10.0 0.237 23.4 23.0 0.4 -0.009 
Prior bup med a,b 50.5 50.8 0.3 0.006 50.9 50.8 0.1 -0.002 
 
c. All prior depression: with IPTW including missing indicator variable for buprenorphine medications 
   Crude (Unweighted) Weighted (stabilized) w missingc 
  OUD wo 
prior DEP 
(n=346) 

















Age Category         
  18-29 37.9 34.5 3.4 -0.071 36.9 36.9 0.0 0.001 
  30-39 36.1 36.7 0.6 0.012 36.2 35.9 0.3 -0.005 
  40-49 15.9 15.0 0.9 -0.025 15.4 16.3 0.9 0.027 
  50+ 10.1 13.9 3.8 0.115 11.5 10.8 0.7 -0.024 
Male sex 59.5 39.7 19.8 -0.404 49.9 49.4 0.5 -0.011 
Non-Hispanic Ethnicity 98.8 98.1 0.7 -0.059 98.0 97.7 0.3 -0.031 
White race 99.4 99.6 0.2 0.030 99.6 99.6 0.0 0.013 
Prior MH dxa 36.7 80.9 44.2 1.003 56.3 57.3 1.0 0.022 
Prior SU dxa 64.2 89.1 24.9 0.617 75.7 77.9 2.2 0.052 
Prior Med dxa 28.9 47.6 18.7 0.391 40.0 38.0 2.0 0.022 
Prior HIV or Hep C dxa 8.4 12.7 4.3 0.142 11.8 11.7 0.1 -0.005 
Prior Chronic Pain dxa 18.8 28.8 10.0 0.237 25.0 26.2 1.2 0.029 


























a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Includes past ordered or dispensed buprenorphine medications 
c Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior Medical dx, 












3.13 Proportions of covariates and standardized differences for past year depression limited to patients with at least a year of observation prior to first 
OUD diagnosis with a) excluding past year mental illness diagnoses from IPTW; b) excluding past year mental illness and substance use disorder 
diagnoses from IPTW 
 
 a. Past year depression: excluding prior mental illness from propensity score model and IPTW 
  Crude (Unweighted) Weighted (stabilized)c 




















Age Category         
  18-29 37.9 33.7 4.2 -0.088 36.2 32.7 3.5 -0.073 
  30-39 36.1 39.4 3.3 0.068 37.6 44.7 7.1 0.147 
  40-49 15.9 14.4 1.5 -0.041 15.5 11.4 4.1 -0.114 
  50+ 10.1 12.5 2.4 0.075 10.7 11.1 0.4 0.015 
Male sex 59.5 43.3 16.2 -0.329 54.7 48.2 6.5 -0.132 
Non-Hispanic 
Ethnicity 
98.8 97.1 1.7 -0.122 98.1 98.4 0.3 0.018 
White race 99.4 100.0 0.6 0.108 100.0 100.0 0.0 0.000 
Prior SU dxa 28.9 73.1 44.2 0.982 39.8 46.5 6.7 0.150 
Prior Med dxa 12.1 40.4 28.3 0.675 19.2 21.9 2.7 0.065 
Prior HIV/ Hep C dxa 1.4 5.8 4.4 0.233 2.8 3.0 0.2 0.014 
Prior chronic pain dxa 6.1 21.2 15.1 0.449 9.7 11.1 1.4 0.042 
Prior bup med a,b 46.5 39.2 7.3 -0.148 44.2 40.2 4.0 -0.082 
 
b. Past year depression: excluding prior mental illness and substance use disorder from propensity score model and IPTW 
  Crude (Unweighted) Weighted (stabilized)c 




















Age Category         
  18-29 37.9 33.7 4.2 -0.088 36.7 35.7 1.0 -0.019 
  30-39 36.1 39.4 3.3 0.068 36.6 37.2 0.6 0.012 
  40-49 15.9 14.4 1.5 -0.041 16.2 18.1 1.9 0.051 
  50+ 10.1 12.5 2.4 0.075 10.5 9.0 1.5 -0.047 
Male sex 59.5 43.3 16.2 -0.329 54.6 52.0 2.6 -0.053 
Non-Hispanic 
Ethnicity 
98.8 97.1 1.7 -0.122 97.4 98.2 0.8 0.057 
White race 99.4 100.0 0.6 0.108 100.0 100.0 0.0 0.000 
Prior Med dxa 12.1 40.4 28.3 0.675 19.0 19.2 0.2 0.007 
Prior HIV/ Hep C dxa 1.4 5.8 4.4 0.233 2.8 3.0 0.2 0.011 
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Prior chronic pain dxa 6.1 21.2 15.1 0.449 10.0 10.1 0.1 0.004 
Prior bup med a,b 46.5 39.2 7.3 -0.148 44.2 43.7 0.5 -0.010 
 
c. Past year depression: with IPTW including missing indicator variable for buprenorphine medications 
  Crude (Unweighted) Weighted (stabilized) w missingc 
  OUD wo 
prior DEP 
(n=346) 







OUD wo prior 
DEP (n=343) 







Age Category         
  18-29 37.9 33.7 4.2 -0.088 35.3 39.8 4.5 0.093 
  30-39 36.1 39.4 3.3 0.068 39.2 38.6 0.6 -0.011 
  40-49 15.9 14.4 1.5 -0.041 14.9 9.2 5.7 -0.157 
  50+ 10.1 12.5 2.4 0.075 10.6 12.4 1.8 0.054 
Male sex 59.5 43.3 16.2 -0.329 54.8 39.6 15.2 -0.309 
Non-Hispanic Ethnicity 98.8 97.1 1.7 -0.122 98.7 98.3 0.4 -0.027 
White race 99.4 100.0 0.6 0.108 100.0 100.0 0.0 0.000 
Prior year MH dxa 14.5 74.0 59.5 1.494 29.7 36.1 6.4 0.150 
Prior year SU dxa 28.9 73.1 44.2 0.982 41.2 48.4 7.2 0.152 
Prior year Med dxa 12.1 40.4 28.3 0.675 20.2 24.4 4.2 0.109 
Prior year HIV or Hep C dxa 1.4 5.8 4.4 0.233 2.2 4.0 1.8 0.092 
Prior year Chronic Pain dxa 6.1 21.2 15.1 0.449 9.0 10.6 1.6 0.054 






















a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Includes past ordered or dispensed buprenorphine medications 
c Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior Medical dx, prior 













3.14 Proportions for each covariate and standardized differences before and after weighting for all prior diagnoses and all observation time 
prior to first OUD diagnosis date 
  Crude (Unweighted) Weighted (stabilized)c 




















Age Category         
  18-29 37.8 34.7 3.1 -0.065 37.5 41.4 3.6 0.080 
  30-39 36.9 36.4 0.5 -0.009 35.6 33.9 1.7 -0.038 
  40-49 15.4 15.3 0.1 -0.003 15.1 15.0 0.1 -0.001 
  50+ 9.8 13.5 3.7 0.114 11.7 9.7 2.0 -0.061 
Male sex 60.0 40.1 19.9 -0.404 51.0 49.8 1.2 -0.026 
Non-Hispanic 
Ethnicity 
97.1 98.2 1.1 0.071 97.4 97.2 0.2 -0.013 
White race 98.7 99.6 0.9 0.106 99.0 99.6 0.6 0.065 
Prior MH dxa 30.4 79.9 49.5 1.146 51.4 52.8 1.4 0.034 
Prior SU dxa 53.2 88.3 35.1 0.835 68.2 70.9 2.7 0.065 
Prior Med dxa 23.7 46.7 23.0 0.495 33.6 34.9 1.3 0.030 
Prior HIV/ Hep C dxa 6.7 12.4 5.7 0.194 10.2 10.0 0.2 -0.007 
Prior chronic pain dxa 14.5 28.5 14.0 0.343 21.8 23.8 2.0 0.051 
Prior bup med a,b 49.5 50.2 0.7 0.013 49.6 51.0 1.4 0.027 
a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Includes past ordered or dispensed buprenorphine medications; Unweighted sample sizes: OUD without prior DEP n=424, OUD with prior DEP 
n=271; Weighted sample sizes: OUD without prior DEP n=423, OUD with prior DEP n=270 
c Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior 












3.15 Proportions for each covariate and standardized differences before and after weighting for past year diagnoses and all observation time 
prior to first OUD diagnosis date 
  Crude (Unweighted) Weighted (stabilized)d 
  OUD wo past 
year DEP 
(n=457) 







OUD wo past 
year DEP 
(n=417) 








Age Category         
  18-29 37.8 34.2 3.6 -0.074 36.9 44.5 7.6 0.159 
  30-39 36.9 38.7 1.8 0.038 38.1 34.3 3.8 -0.078 
  40-49 15.4 15.3 0.1 -.003 14.5 9.2 5.3 -0.148 
  50+ 9.8 11.7 1.9 0.060 10.5 12.0 1.5 0.049 
Male sex 60.0 44.1 15.9 -0.320 56.0 42.9 13.1 -0.266 
Non-Hispanic Ethnicity 97.1 97.3 0.2 0.013 97.9 98.0 0.1 0.010 
White race 98.7 100.0 1.3 0.165 100.0 100.0 0.0 0.000 
Prior year MI dxb 13.2 72.1 58.9 1.477 27.1 32.7 5.6 0.142 
Prior year SUD dxb 26.0 72.1 46.1 1.037 37.6 44.5 6.9 0.155 
Prior year Med dxb 10.7 38.7 28.0 0.684 18.1 24.2 6.1 0.149 
Prior year HIV/ Hep C dxb 1.3 5.4 4.1 0.226 1.6 2.7 1.1 0.058 
Prior year chronic pain dxb 4.7 20.7 16.0 0.494 7.9 10.0 2.1 0.062 
Prior year bup medb,c 46.5 38.5 8.0 -0.160 44.2 36.9 7.3 -0.148 
a OUD without past year DEP= no depression OR depression on/after first OUD dx (n=447); OUD with past year DEP=had at least one depression 
code within year prior to first OUD dx (n=111); Patients that had a depression code more than a year prior to the first OUD dx and didn’t have 
another are excluded (n=163) 
b The definition of all of these DO NOT include the day of OUD dx (e.g. within 1 year prior to first OUD dx date) 
c Includes past ordered or dispensed buprenorphine medications; Unweighted sample sizes: OUD without prior DEP n=424, OUD with prior DEP 
n=109; Weighted sample sizes: OUD without prior DEP n=417, OUD with prior DEP n=109 
d Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior year mental illness diagnosis code, 
prior year substance use disorder diagnosis code, prior year Medical diagnosis code, prior year HIV or Hep C diagnosis code, prior year chronic pain 




















Chapter 4: The role of comorbid depression in the continuity of 
















Background: Ongoing opioid agonist treatment, including methadone and buprenorphine, is 
associated with positive treatment outcomes. However, challenges with continuation and 
retention in opioid agonist treatment exist. Psychiatric comorbidities are associated with lower 
retention in substance use treatment, but this is not always consistent with opioid agonist 
treatment. Opioid use disorder and depression are highly comorbid and depression could impact 
the continuation and retention in buprenorphine treatment. The current study assessed differences 
in buprenorphine treatment continuity and retention among persons with opioid use disorder with 
and without co-occurring depression. 
Methods: Records for ordered prescriptions placed within the Geisinger Health System between 
2018 and 2019 were analyzed for patients who had an opioid use disorder and initiated 
buprenorphine treatment at specialty outpatient substance use treatment clinic (N=517). Co-
occurring depression was defined as having any prior or past year depression diagnoses. We used 
propensity score weighted logistic regression to estimate odds of 180-day retention and any 
treatment discontinuation, and propensity score weighted cox proportional hazards regression to 
estimate hazard of treatment gaps or discontinuation for those with and without depression. 
Results: Forty percent of the study sample remained in treatment at 180 days without any 
treatment gaps or discontinuation. Any prior or past year depression was associated with 
increased risk of treatment gap and/or discontinuation of treatment (any prior: weighted HR 1.54, 
95% CI 1.11, 2.14; past year: weighted HR 1.84, 95% CI 1.16, 2.94). Past year depression was 
associated with decreased odds of 180-day retention (weighted OR 0.31; 95% CI 0.12, 0.79). 
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Conclusions: The association between co-occurring depression and opioid agonist treatment 
course and outcomes is not clear-cut, and the results of the current study further demonstrate this 
complexity. The results suggests that assessing and managing depression may be important for 




































 Over two million adults in the US met the criteria for an opioid use disorder in 2018.11 
Opioid use disorder is associated with increased risk of mortality, as well as other health 
conditions and social adversity.109 However, effective treatment for opioid use disorder exists 
and its expansion is crucial for reducing morbidity and mortality associated with opioid use 
disorder. The use of opioid agonist medications, including methadone and buprenorphine, is the 
gold standard for the treatment of opioid use disorder (OUD).32 Buprenorphine which is most 
typically prescribed through office-based or outpatient treatment is the focus of this study. 
Buprenorphine is a partial opioid agonist and has been found to be effective in the treatment of 
OUD in clinical trials,37,44 as well as a number of observational studies. Buprenorphine is 
effective in reducing opioid withdrawal symptoms and decreasing use of opioids.44,110 Compared 
to non-medication based treatment, buprenorphine is associated with reductions in other adverse 
effects of OUD including criminal justice involvement, HIV and Hepatitis C transmission and 
overdose death.27,37–41 Buprenorphine is also associated with greater treatment retention37 and 
ongoing maintenance is particularly crucial in treating OUD and reducing adverse 
consequences.60,111,112 
  Even with the strong evidence base for the use of agonist medications to treat OUD, 
significant barriers to accessing and utilizing medication for opioid use disorder (MOUD) exist, 
leading to less than 30% of people with OUD receiving medication as part of their treatment 
plan.113 In the US, healthcare providers must have an approved waiver to prescribe 
buprenorphine. Even though the prevalence of buprenorphine-waivered providers increased from 
3.8 per 100,000 persons in 2007 to 17.3 per 100,000 persons in 2017, this corresponds to fewer 
than 10% of providers in the US.36 The expansion of waivered providers was also not uniform 
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across communities. The growth of buprenorphine waivered providers was slower in non-
metropolitan counties compared to metropolitan counties. Furthermore, counties with lower 
levels of education overall also had slower growth compared to those with higher education 
levels.36 Even though the percentage of outpatient substance use treatment facilities that offer 
buprenorphine has increased in recent years, as of 2016 only 25% of these facilities offered 
buprenorphine.35  
  Even among individuals with OUD who do receive treatment with MOUD, challenges 
with low adherence and treatment retention exist.114 Ongoing maintenance treatment with 
buprenorphine is associated with better outcomes. Current clinical guidelines recommend a 
minimum of 180 days of treatment with MOUD, but continued treatment without a specific 
duration is advised.115,116 A number of studies have explored risk factors for MOUD continuity 
and discontinuity. At the patient-level, male sex, younger age, and non-white race and Hispanic 
ethnicity status are associated with earlier discontinuation of buprenorphine treatment.48,117 Other 
substance use and medical comorbidities including chronic pain and Hepatitis C were also found 
to be associated with greater risk of discontinuation.48  
The role of psychiatric comorbidities in the course of opioid agonist treatment for OUD is 
unclear. While it is well established that psychiatric comorbidity is associated with reduced 
access and lower retention to substance use treatment overall,22,23 evidence is less clear for 
opioid agonist treatment. Krawcyzk and colleagues used a national dataset of substance use 
treatment programs in the US and found no association between psychiatric comorbidity and 
opioid agonist treatment non-completion and a weak association with time to attrition from 
agonist treatment.22 In another study utilizing Medicaid claims, Samples and colleagues also did 
not find an association between psychiatric comorbidities, including depression, anxiety, post-
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traumatic stress disorder, bipolar disorder and schizophrenia, and minimum treatment duration or 
time to buprenorphine treatment discontinuation.48  
Among persons with OUD, depression is the most common psychiatric comorbidity.16 
Research examining the relationship between depression and opioid agonist treatment course is 
mixed with some studies finding no effect48 and others finding depression associated with 
positive treatment outcomes.53 A limitation of existing studies is relatively short duration of 
treatment follow-up of 12 weeks.53,54 
Given the prevalence of depression among persons with OUD, more research examining 
the relationship between co-occurring depression and course of buprenorphine treatment is 
needed. Longer follow-up is particularly necessary, as ongoing buprenorphine treatment leads to 
better outcomes. The current study aimed to explore the association between depression with 
gaps, discontinuation and retention in buprenorphine treatment for OUD. We utilized data on 
ordered prescriptions over time for patients who initiated buprenorphine treatment at a specialty 
treatment facility within an integrated healthcare system in Pennsylvania. 
4.2 Methods 
 
Study setting and sample 
Data on prescription medications ordered by prescribers for patients in the Geisinger 
Health System was used to assess buprenorphine treatment course. Patients included in the 
sample were recruited from one of four outpatient substance use treatment clinics within the 
Geisinger Health System starting in the spring of 2017. The primary treatment model in these 
clinics utilizes buprenorphine or naltrexone to treat OUD. These clinics also provide other 
services including counseling and care coordination to address other social factors impacting 
clinic patients. Treatment information is embedded into the electronic health records of the 
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Geisinger Health system with the consent of patients receiving care. Specific details of the model 
used at these addiction medicine clinics are provided elsewhere.74  
For patients recruited from one of these outpatient treatment clinics, all electronic health 
records and prescription medication orders up until fall 2019 were used. Across all patients in the 
study, there was an average of 248 days of follow-up after the start of treatment. In order for a 
patient to be included in the study sample, they must have met the following criteria: 1) at least 
one OUD diagnosis code; 2) at least 18 years old at the date of first OUD code; 3) at least one 
ordered buprenorphine prescription; 4) at least one visit at one of the four Geisinger outpatient 
treatment clinics; and 5) at least one year of electronic health records data prior to the date of 
first OUD diagnosis. The prescription records also included a limited number of buprenorphine 
prescriptions in inpatient settings. These prescription records were excluded. The final analytic 
sample included 517 adults and 9,729 buprenorphine prescriptions. The current study does not 
qualify as human subjects research as determined by Geisinger and Johns Hopkins Bloomberg 
School of Public Health Intuitional Review Boards. 
Independent measures 
 
Primary exposure and covariates. All patients in the study sample had at least one OUD 
diagnosis code in their electronic health records. The primary exposure variable of interest was a 
depression diagnosis code prior to the date of first OUD diagnosis. Because the association of 
buprenorphine treatment continuity with depression may vary according to the recency of 
depression, analyses were conducted once for all depressive disorders diagnosed before the first 
OUD diagnosis in the system and separately for depression diagnoses within 12 months prior to 
first OUD diagnosis. Other covariates included sex, age at OUD diagnosis date, race, ethnicity, 
mental illness (MI) other than depression, substance use disorder (SUD) other than OUD, HIV or 
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Hepatitis C diagnosis, chronic pain diagnosis, and other common medical diagnoses 
(hypertension, diabetes mellitus, and disorders of the airway including chronic obstructive 
pulmonary disease [COPD] and asthma), all prior to date of first OUD diagnosis. All medical 
and mental health and substance use diagnoses were defined using ICD 9 or 10 codes listed in 
Supplemental Table 4.1. 
Buprenorphine products. All oral and extended-release injectable buprenorphine 
formulations were included (Table of all medications is included in Supplemental Table 4.2). 
Outcome measures 
1. Treatment gap was defined by an absence of buprenorphine prescriptions for at least 
14 days but less than 30 days for non-extended release formulations,117 and at least 44 days but 
less than 60 days for extended release formulations. 
2. Treatment discontinuation was defined by an absence of buprenorphine prescriptions 
of 30 days or longer for non-extended release formulations48 and 60 or longer for extended 
release formulations. For extended release formulations, the definition was based on a typical 
once-monthly injection. 
3. Total treatment length was quantified as the total number of days between first 
outpatient substance use clinic visit date with a buprenorphine prescription and date of last 
buprenorphine prescription in ordered prescription records.     
4. Treatment retention was a binary measure of treatment of at least 180 days without 
treatment gaps or discontinuation following first clinic visit.48,117 
5. Treatment continuity was a time-to-event measure assessed by the total number of days 
between first buprenorphine prescription and the first day of discontinuation or gap. 
Analyses 
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The goal of this study was to compare medication continuity and discontinuity between 
individuals with and without depression. To do this we used propensity score weighted 
regression models. The propensity score methods were used to account for potential confounding 
variables and to create groups with and without prior depression with a balanced distribution of 
observed covariates, stabilized inverse probability of treatment weights (IPTW) were calculated 
from propensity scores derived using logistic regression. Separate weights were computed for the 
two exposures of interest: OUD with any prior depression and OUD with past year depression. 
For any prior depression, propensity scores were constructed using patient characteristics and 
relevant diagnoses that occurred at any point prior to first OUD diagnosis, including other mental 
health disorders, other substance use disorders, medical conditions, HIV or Hepatitis C, and 
chronic pain, as well as any ordered buprenorphine prescriptions. For past year depression, 
patient characteristics and diagnostic codes that occurred within the year prior to first OUD 
diagnosis were used to construct propensity scores. After applying IPTW, we observed 
substantial reductions in differences in the distribution of covariates between the OUD without 
prior depression and OUD with prior depression and past year depression groups. Crude and 
standardized differences in covariate proportions are presented in Supplemental Tables 4.3 and 
4.4. Absolute standardized mean differences are used to assess covariate balance with propensity 
score methods. In prior research, thresholds of 0.1 and 0.25 have been used to identify 
imbalance.100 For all prior depression, after applying weights, standardized differences for all 
covariates were less than 0.1. After applying weights for past year depression, the absolute 
standardized difference was greater than 0.1 for age categories 18-29 and 40-49, past year mental 
illness diagnoses and past year substance use disorder diagnoses. The standardized difference for 
sex was greater than 0.25 (Supplemental Table 4.4). To account for potential imbalance after 
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applying weights, we also included these imbalanced variables in the weighted regression 
models for past year depression. 
Weighted regression models were used to then examine the association between 1) any 
depression; and 2) past year depression with each of the outcomes. For binary outcomes (180-
day retention and treatment discontinuation), logistic regression was used to obtain unweighted 
and propensity score weighted odds ratios. Weighted regression models also included time since 
OUD diagnosis, time since first buprenorphine prescription (if occurred prior to first clinic visit), 
and time between first clinic visit and last buprenorphine prescription record.  
For days to gap or discontinuation, and days to treatment discontinuation, we used Cox 
proportional hazards model to calculate unweighted and propensity-score weighted proportional 
hazards ratios. The time origin was first clinic date with a buprenorphine prescription. In addition 
to IPTW, in these analyses we also adjusted for time since OUD diagnosis and time since first 
buprenorphine prescription (if they occurred prior to first clinic visit). Robust standard errors 
were applied to account for correlated observations (multiple prescriptions) per patient.102 
Weighted Kaplan-Meier survival curves for treatment gaps or discontinuation and treatment 
discontinuation based on depression exposure were also plotted. All analyses were conducted 
using Stata 14.2. 
Sensitivity analyses 
 Because of prescribing and procedural differences between extended-release and non- 
extended-release buprenorphine products, we repeated all analyses after excluding patients who 
had any extended-release buprenorphine prescriptions (n=37). We also re-ran models excluding 







 Unweighted descriptive information of patient demographic characteristics and diagnoses 
is presented in Table 4.1. Relative to patients with OUD without co-occurring depression, a 
larger proportion of patients with OUD and co-occurring depression (both any depression 
diagnoses captured prior to OUD diagnosis for a given patient and depression diagnoses in the 
year prior to OUD diagnosis) were female and had other co-occurring health conditions. Without 
accounting for gaps, the average number of days between the first clinic date and last 
buprenorphine prescription was 248 days for patients without a prior depression diagnosis, 282 
days for those with any prior depression diagnosis and 344 days for those with a past year 
depression diagnosis (Table 4.2).  
 Thirty-three percent of patients with OUD without depression had at least one treatment 
gap or discontinuation, whereas 41.9% with prior depression (p=0.03) and 50% with past year 
depression (p=0.004) had at least one gap or discontinuation. Overall, 16.7% of patients without 
depression, 20.7% of those with any prior depression (p=0.24) and 28.1% with past year 
depression (p=0.02) discontinued treatment at least once. The proportion of patients on 
buprenorphine for at least 180 days without gaps or discontinuation were 38.3% for OUD 
without depression, 41.0% for OUD with any prior depression (p=0.54) and 46.3% for OUD 
with past year depression (p=0.19) (Table 4.2). 
Differences in any discontinuation and 6-month retention by depression exposure group 
 After applying IPTW, compared to patients with OUD but no prior depression, patients 
with OUD and past year depression had decreased odds of 6-month retention (weighted odds 
ratio (OR) 0.31; 95% CI 0.12, 0.79) and increased odds of any treatment discontinuation 
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(weighted OR 2.50; 95% CI 1.08, 5.75). There were no significant differences in odds of 6-
month retention or odds of any treatment discontinuation between individuals with OUD without 
prior depression and individuals with OUD with any prior depression (Table 4.3).  
Risk of gap or discontinuation by depression exposure group 
 Hazard ratios comparing incidence of treatment gaps and discontinuation between adults 
with OUD without prior depression and those with OUD and any prior or past year depression 
are presented in Table 4.4. Compared to patients without prior depression, patients with any prior 
depression or past year depression had an increased hazard of a treatment gap or discontinuation 
(any prior depression: weighted HR 1.54, 95% CI 1.11, 2.14; past year depression: weighted HR 
1.84, 95% CI 1.16, 2.94) and treatment discontinuation (any prior depression: weighted HR 1.63, 
95% CI 1.01, 2.63; past year depression: weighted HR 2.04, 95% CI 1.08, 3.87). Figure 4.1 
displays weighted survival curves for each outcome. 
Sensitivity analyses 
 
 After excluding patients who had any extended release buprenorphine prescriptions, past 
year depression was no longer associated with odds of 6-month retention or any discontinuation, 
although the direction and magnitude of the odds ratios did not change meaningfully (6-month 
retention: weighted OR 0.60, 95% CI 0.20, 1.83; any discontinuation: weighted OR 1.45, 95% 
CI 0.43, 4.86). Past year depression was also no longer significantly associated with increased 
hazard of gap or discontinuation, but was still associated with increased rate of discontinuation. 
However, as with the binary outcomes the direction and strength of the effect was similar 
(weighted HR 1.64, 95% CI 0.92, 2.94). After excluding patients who had a first buprenorphine 
prescription order after their first medication clinic visit date, past year depression was no longer 
significantly associated with decreased odds of 6-month retention (weighted OR 0.41, 95% CI 
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0.16, 10.5) or odds of any discontinuation (weighted OR 2.34, 95% CI 0.96, 5.71). Also, any 
prior and past year depression were no longer significantly associated with increased hazard of 
discontinuation (all prior weighted HR 1.64, 95% CI 0.99, 2.70; past year weighted HR 1.85, 
95% CI 0.96,3.54). The direction and magnitude of the effects were similar to the main analyses.  
4.4 Discussion 
 
The current study examined differences in continuity of and retention in buprenorphine 
treatment for OUD among persons with and without a prior depression diagnosis. Similar to 
prior studies,48,117 we found that only 39.5% of the overall patient sample remained in treatment 
at 6-months without any treatment gaps or discontinuation. As compared to those without a prior 
depression diagnosis, persons who had any prior or past year depression diagnoses had increased 
risk of a treatment gap and/or discontinuation of treatment. Persons with past year depression 
were less likely to still be in buprenorphine treatment at 180 days. 
Across substance use treatment outcomes, psychiatric comorbidities including depression 
have been found to be associated with reduced access and lower retention.22,23 However, this 
association between course and outcomes of opioid agonist treatment, including both 
buprenorphine and methadone, and psychiatric comorbidity,22,50,118 and specifically 
depression,48,53,119,120 is not as straightforward. The results of our study further add to the 
complexity of this relationship. We found persons with OUD and any prior or past year 
depression had greater risk of a gap in their buprenorphine prescriptions, as well as a greater risk 
of discontinuing treatment. We also found that patients with a depression diagnosis in the year 
prior to their first OUD diagnosis were less likely to still be receiving buprenorphine 
prescriptions at 180 days. This could be impacted by a number of factors. It may be that 
symptoms of depression impact a person’s ability to adhere to treatment regimen and 
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requirements of the clinic where they are receiving treatment, and thus also influence treatment 
continuity and discontinuation. Prior studies have also found that persons with co-occurring 
mental health disorders, including depression, may have more complex treatment needs. Many 
have other medical comorbidities and social factors that are not always incorporated into 
substance use treatment programs, including medication based treatment for OUD.86,121,122 This 
is also true for our study population, in which the majority for persons with a prior depression 
diagnosis also had another mental health or substance use disorder. Almost 50% had a prior 
medical diagnosis, including hypertension, diabetes mellitus, COPD and/or asthma, and 31% had 
a prior chronic pain diagnosis. However, we utilized propensity score methods to create groups 
with and without depression with similar covariate balance with the goal of separating the effect 
of depression from the effects of pre-existing differences in observed covariates. Therefore, the 
results suggest that depression may be playing a key role in continuity and retention in treatment. 
 We were unable to assess changes in depressive symptoms among the study population. 
However, prior research suggests that buprenorphine is associated with improvement in 
depressive symptoms.123 This could be because of antidepressant properties of buprenorphine. A 
partial opioid agonist, buprenorphine is a mu receptor agonist and kappa receptor antagonist. The 
kappa receptor system is involved in the expression of depressive symptoms and kappa agonists 
increase depressive symptoms including dysphoria. Thus, kappa antagonist properties of 
buprenorphine may counteract these effects and improve depressive symptoms among 
patients.124,125  It is important to extend this understanding by exploring changes in depression 
with longer term buprenorphine treatment and further assess how these changes in depressive 
symptoms might influence course of treatment and outcomes. 
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In this study we did not examine the possible moderating effect of depression treatments, 
and specifically antidepressant medications, in the association of depression with buprenorphine 
treatment continuity. However, past research has found scant evidence for any beneficial effects 
of antidepressant treatments on opioid agonist treatment outcomes or reduction in depressive 
symptoms among persons with co-occurring OUD and depression.57,123 Although, the addition of 
psychotherapies may be helpful in reducing symptoms of distress among this population.123 
More research is needed on the potential benefit of psychotherapies on buprenorphine treatment 
outcomes among persons with co-occurring OUD and depression. Lastly, it would be interesting 
to explore potential differences in support group participation, as well as the role of instrumental 
support in treatment retention particularly for individuals with co-occurring depression. 
Limitations 
 As with other studies assessing this complex relationship between opioid agonist 
treatment and depression, there are a number of limitations related to measurement that need to 
be considered. First, we relied on diagnostic codes from electronic health records to define OUD, 
depression and other health conditions which rely on the consistency and accuracy of the 
recordings by healthcare providers. However, because this population was recruited from an 
outpatient substance use treatment clinic, addiction specialists verified the OUD diagnosis. Also, 
differences in observation time prior to first OUD diagnosis could impact likelihood of receiving 
diagnoses because of differences in contact with the health system. While some of this variation 
could be accounted for by including age in the propensity score model, as well as limiting to past 
year diagnoses, future plans include accounting for this. We also note that each time we use “first 
date,” it is referring to the first date in the electronic health records or prescription medication 
database, which may or may not be a person’s first ever diagnosis or prescription. Relying on 
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ordered buprenorphine prescriptions to measure continuity and retention in treatment may also 
create some limitations because receiving a prescriptions is not necessarily an indicator of taking 
a medication. To mitigate this, we chose to only include patients who initiated treatment at one 
of the Geisinger clinics, which have detailed protocols to track treatment compliance. 
Additionally, after excluding patients based on having extended release buprenorphine 
prescriptions and those whose first buprenorphine prescription was after their first clinic date, we 
lost statistical significance for some of the results. This could be because of the reduction in 
sample size, however future research should examine this more closely, particularly for treatment 
including extended release buprenorphine formulations. Also, clinic differences, such as location 
and providers, could influence treatment course and outcomes; we plan to request this 
information and then account for it in future analyses. Lastly, the study sample includes almost 
exclusively white non-Hispanic patients receiving healthcare in rural Pennsylvania. Therefore, 
the results may not generalize to more racially diverse and urban populations. 
Conclusions 
 The results of the current study suggest that prior depression is relatively common among 
patients with OUD and, often associated with other comorbidities. Furthermore, depression is 
associated with reduced continuity and retention in buprenorphine treatment. These findings 
highlight the need for improved depression care, ideally in the context of integrated services, for 













Table 4.1 Unweighted sample characteristics and prior diagnoses in the electronic health records 
(N=517) 
 OUD without 
prior depression 
(n=300) 
OUD with any 
prior depression 
(n=217) 
OUD with any past 
year depression 
(n=82) 
Demographic characteristics % % % 
Male sex 57.3 38.7 42.7 
Age groupa    
  18-29 37.0 32.7 34.2 
  30-39 36.3 36.3 39.0 
  40-49 16.3 16.1 15.9 
  50+ 10.3 11.8 11.0 
Non-Hispanic ethnicity 99.0 97.7 96.3 
White race 99.3 99.5 100.0 
Any prior diagnoses or prescription    
Mental illness 37.0 79.7 -- 
Substance use disorder 64.7 88.0 -- 
Chronic pain 20.3 30.9 -- 
HIV or Hepatitis C 9.0 11.5 -- 
Other medical conditiona 31.0 47.9 -- 
Buprenorphine prescriptionb 3.7 11.1 -- 
Past year diagnoses or prescription    
Mental illness 15.0 -- 73.2 
Substance use disorder 27.3 -- 69.5 
Chronic pain 6.7 -- 23.2 
HIV or Hepatitis C 1.7 -- 4.9 
Other medical conditiona 13.0 -- 39.0 
Buprenorphine prescriptionb 1.0 -- 3.7 
a Other medical conditions include hypertension, diabetes mellitus, and chronic obstructive pulmonary 
disease and asthma 
b Ordered 
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Table 4.2 Description of first dates of opioid use disorder, buprenorphine order and medication clinic, and frequency of treatment 
outcomes by exposure group  
 Total sample (n=517) OUD without prior 
depression (n=300) 
OUD with any prior 
depression (n=217) 
OUD with any past year 
depression (n=82) 
First dates Median [range] Median [range] Median [range] Median [range] 
























Buprenorphine treatment outcomes Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Total length (without gaps)a 262.1 (196.0) 247.6 (186.5) 282.1 (207.2) 343.6 (219.9)** 
 n (%) Mean # (SD) n (%) Mean # (SD) n (%) Mean # (SD) n (%) Mean # (SD) 
Any gapb 118 (22.8) 0.27 (0.56) 58 (19.3) 0.23 (0.51) 60 (27.7)* 0.34 (0.61) 26 (31.7)* 0.40 (0.66) 
Number of gaps         
0 399 (77.2)  242 (80.7)  157 (72.4)  56 (68.3)  
1 99 (19.2)  49 (16.3)  50 (23.0)  20 (24.4)  
2 or more 19 (3.6)  9 (3.0)  10 (4.6)  6 (7.3)  
Any discontinuationb 95 (18.4) 0.22 (0.51) 50 (16.7) 0.20 (0.50) 45 (20.7) 0.24 (0.52) 23 (28.1)* 0.37 (0.66) 
Number of discontinuations         
0 422 (81.6)  250 (83.3)  172 (79.3)  59 (72.0)  
1 82 (15.9)  44 (14.7)  38 (17.5)  17 (20.7)  
2 or more 13 (2.5)  6 (2.0)  7 (3.2)  6 (7.3)  
Any gap or discontinuationb 189 (36.6) 0.49 (0.77) 98 (32.7) 0.43 (0.72) 91 (41.9)* 0.58 (0.84) 41 (50.0)* 0.77 (0.99) 
Number of gaps or discontinuations     
0 328 (63.4) 202 (67.3) 126 (58.1) 41 (50.0) 
1 142 (27.5) 76 (25.3) 66 (30.4) 26 (31.7) 
2 or more 47 (9.1) 22 (7.3) 25 (11.5) 15 (18.3) 
 n (%) n (%) n (%) n (%) 
180-day retentionc 204 (39.5) 115 (38.3) 89 (41.0) 38 (46.3) 
* p<0.05; reference group OUD without depression 
** p<0.01; reference group OUD without depression 
a Total length of time between first and last clinic date (in days) 
b At least one 






Table 4.3 Buprenorphine retention and discontinuation comparing adults with OUD without prior depression and those with OUD any 
prior/past year depression (Any prior depression: N=517, Past year depression: N=382) 
a Continuous (without gaps or discontinuation) 
b Defined as 30 or more days between buprenorphine prescriptions (60 days for extended release formulations) 
c Stabilized IPTW for all prior depression; adjusted for the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI 
dx, prior SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx 
d Regression model adjusted for time since first OUD diagnosis, time since first buprenorphine prescription (if occurred prior) and time between 
first and last medication-based clinic visit 
e Stabilized IPTW for past year depression; adjusted for the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year 
MI dx, past year SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx 
f Doubly robust model including sex, age categories 19-29 and 40-49, past year mental health disorder and past year substance use disorder in 























 180 day retentiona Any discontinuationb 
 OR [95% CI] Weighted OR [95% CI]c-e OR [95% CI] Weighted OR [95% CI]c-e 
Any prior depression 1.12 [0.78, 1.60] 0.57 [0.33, 0.99] 1.31 [0.84, 2.05] 1.71 [0.97, 3.00] 
Past year depression 1.39 [0.85, 2.27] 0.31 [0.12, 0.79]f 1.95 [1.10, 3.44] 2.50 [1.08, 5.75]f 
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Table 4.4 Hazard ratios with 95% confidence intervals (CI) for comparing incidence of treatment gaps and discontinuation between adults 
with OUD without prior depression (reference) and OUD with any prior/past year depression 




rate per 1000 
person-years 
Crude Hazard 















All prior depressiona,b 189 1.95 1.25 [0.94, 1.66] 1.54 [1.11, 2.14] 95 0.85 1.22 [0.81, 1.82] 1.63 [1.01, 2.63] 
Past year depressionc,d 139 1.90 1.37 [0.95, 2.00] 1.84 [1.16, 2.94] 73 0.87 1.60 [0.97 2.65] 2.04 [1.08, 3.87] 
a Crude N=517 
b IPTW N=512 
c Crude N=382 
d IPTW N=370 
e Stabilized IPTW for all prior depression; adjusted for the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior SUD 
dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
f Stabilized IPTW for past year depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past 
year SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered) 
g For all prior depression, regression model adjusted for time since first OUD diagnosis and time since first buprenorphine prescription (if occurred prior) 
h For past year depression, regression model adjusted for sex, age categories 19-29 and 40-49, past year mental health disorder and past year substance use disorder, 























Figure 4.1 Kaplan Meier survival curves for A) Gaps or discontinuations in buprenorphine treatment according to any prior depression 
diagnoses; B) Gaps or discontinuations in buprenorphine treatment according to past year depression diagnosis; C) Discontinuation in 
buprenorphine treatment according to any prior depression diagnoses; and D) Discontinuation in buprenorphine treatment according to 
past year depression diagnoses. All analyses weighted by Inverse Probability of Treatment Weights. 
 




































Supplemental Table 4.1 ICD 9 and ICD 10 codes used to define diagnoses  
Diagnosis categories Diagnosis Included 
Mental health and Substance use   
Opioid use disorder ICD9: 304, 304.0, 304.00-.02, 305.5, 305.50-.52 
ICD10: F11, F11.1, F11.10, F11.12, F11.120-.122, F11.129, F11.14, F11.15, 
F11.150-.151, F11.159, F11.18, F11.181-.182, F11.188, F11.19, F11.2, 
F11.20, F11.22, F11.220-.222", F11.229, F11.23-.25, F11.250-.251, F11.259, 
F11.28, F11.281-.282, F11.288, F11.29, F11.9, F11.90, F11.92, F11.920-
.922, F11.929, F11.93-.95, F11.950-.951, F11.959, F11.98, F11.981-.982, 
F11.988, F11.99 
Depressive disorders ICD9: 296.2*, 296.3*, 300.4*, 311 
ICD10: F32*, F33*, F34.1 
Other substance use disorder ICD9: 303*, 304.1*, 304.2*, 304.3*, 304.4*, 304.5*, 304.6*, 304.8*, 304.9*, 
305.0*, 305.1*,305.2*, 305.3*, 305.4*, 305.6*, 305.7*, 305.9* 
ICD10: F10*, F12*-F19*, F55* 
Other mental health disorder  ICD9: 290*-296*, 297*-299*, 300*, 301*, 302*, 308*, 309* 
ICD10: F01*-F09*, F20*-F25*, F28*-F29*,  F31*, F34*, F39, F40*, F41.0, 
F41.1, F41.3, F41.8, F41.9, F42*-F45*, F48*, F50*-F52*, F54*, F59*, F60*, 
F63*-F69*, F99* 
Other medical   
Chronic pain  ICD9: 338.2*, 338.4,  
ICD10: G89.2*, G89.4 
HIV and Hepatitis C ICD9: 042, 070.41, 070.44, 070.51, 070.54, 070.71 
ICD10: B20, B17.1*, B18.2, B19.2* 
Other (includes hypertensive disease, diabetes mellitus, 
disorders of the airway-COPD and asthma) 
ICD9: 401*-405*, 205*, 490*-496* 













Supplemental Table 4.2 List of Buprenorphine products, formulations and routes 
Ordered Buprenorphine Medications  
Buprenorphine products Total overall=9,729 prescriptions (n, %) 
Buprenorphine HCL (437, 4.5%) 
Buprenorphine HCL-Naloxone HCL (9,114, 93.7%) 
Buprenorphine ER (53, 0.5%) 
Sublocade (2, 0.02%) 
Suboxone, film and sublingual (112, 1.15%) 
Zubsolv, sublingual (11, 0.11%) 
Buprenorphine formulations Film (5,011, 51.5%) 
SL Tab (4,663, 47.9%) 
Solution prefilled syringe (55, 0.6%) 
Buprenorphine routes Subcutaneous (55, 0.6%) 


























Supplemental Table 4.3 Proportions for each covariate and standardized differences comparing opioid use disorder without any prior 
depression and opioid use disorder with any prior depression before and after weighting for all prior diagnoses limited to patients with at 
least a year of observation prior to first opioid use disorder diagnosis  
  Crude (Unweighted) Weighted (stabilized)b 




















Age Category         
  18-29 37.0 32.7 4.3 -0.090 35.4 37.6 2.2 0.047 
  30-39 36.3 36.3 0.0 0.021 37.2 35.5 1.7 -0.035 
  40-49 16.3 16.1 0.2 -0.006 15.8 16.0 0.2 0.107 
  50+ 10.3 11.8 0.5 0.107 11.6 10.9 0.7 -0.023 
Male sex 57.3 38.7 18.6 -0.379 48.4 48.4 0.0 -0.021 
Non-Hispanic Ethnicity 99.0 97.7 1.3 -0.103 97.7 97.8 0.1 0.007 
White race 99.3 99.5 0.2 0.027 99.5 99.6 0.1 0.015 
Prior MH dx 37.0 79.7 42.7 0.960 55.5 57.6 2.1 0.048 
Prior SU dxa 64.7 88.0 23.3 0.570 75.5 77.3 1.8 0.044 
Prior Med dxa 31.0 47.9 16.9 0.351 37.4 38.9 1.5 0.032 
Prior HIV/ Hep C dxa 9.0 11.5 2.5 0.083 11.2 11.2 0.0 -0.000 
Prior chronic pain dxa 20.3 30.9 10.6 0.243 25.2 26.1 0.9 0.022 
Prior buprenorphine rxa 3.7 11.1 7.4 0.285 7.2 7.5 0.3 0.014 
a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior 
















Supplemental Table 4.4 Proportions for each covariate and standardized differences comparing opioid use disorder without past year 
depression and opioid use disorder with past year depression before and after weighting for all past year diagnoses limited to patients with at 
least a year of observation prior to first opioid use disorder diagnosis  
a The definition of all of these DO NOT include the day of OUD dx (e.g. within 1 year prior to first OUD dx date) 
b Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior year MI dx, prior year SUD dx, 













  Crude (Unweighted) Weighted (stabilized)b 
  OUD wo past 
year DEP 
(n=300) 







OUD wo past 
year DEP 
(n=298) 







Age Category         
  18-29 37.0 34.2 2.8 -0.059 34.8 39.8 4.8 0.105 
  30-39 36.3 39.0 2.7 0.055 38.9 39.2 0.6 0.005 
  40-49 16.3 15.9 0.4 -0.013 15.4 8.9 6.6 -0.176 
  50+ 10.3 11.0 0.7 0.021 10.9 12.1 1.2 0.040 
Male sex 57.3 42.7 14.6 -0.295 54.0 36.8 16.8 -0.347 
Non-Hispanic Ethnicity 99.0 96.3 2.7 -0.176 98.5 98.0 0.5 -0.035 
White race 99.3 100.0 0.7 0.116 100.0 100.0 0.0 0.000 
Prior year MH dxa 15.0 73.2 58.2 1.439 28.2 34.5 6.1 0.156 
Prior year SU dxa 27.3 69.5 42.2 0.927 37.9 42.8 5.2 0.108 
Prior year Med dxa 13.0 39.0 26.0 0.618 19.5 23.1 4.0 0.086 
Prior year HIV/ Hep C dxa 1.7 4.9 3.2 0.180 2.2 3.7 1.4 0.083 
Prior year chronic pain dxa 6.7 23.2 16.5 0.474 9.8 10.8 1.0 0.031 
Prior year buprenorphine rxa 1.0 3.7 2.7 0.176 1.8 2.5 0.7 0.044 
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Chapter 4 Appendices 
 
4.1 Timing between 1) First opioid use disorder diagnosis in EHR and first buprenorphine ordered prescription; 2) First opioid use disorder 
diagnosis in EHR and first medication-based treatment clinic; 3) ) First buprenorphine ordered prescription and first medication-based treatment 
clinic 
 Total sample (n=517) OUD without prior 
depression (n=300) 
OUD with any prior 
depression (n=217) 
OUD with any past year 
depression (n=82) 
OUD dx timing (first Bup 
order) 
n (%) Median days 
[range] 
n (%) Median days 
[range] 
n (%) Median days 
[range] 
n (%) Median days 
[range] 
First OUD dx before first 
bup order 
186 (36.0) 586.5 [1, 7499] 108 (36.0) 665.5 [3, 7499] 78 (35.9) 494 [1, 4899] 38 (46.4) 568.5 [1, 4899] 
First OUD dx on same day 
as first bup order 
308 (59.8) 187 (62.3) 121 (55.8) 41 (50.0) 
First OUD dx after first 
bup order 
23 (4.5) 3127 [7, 5392] 5 (1.7) 392 [185, 4511] 18 (8.3) 3718 [7, 5392] 3 (3.6) 2600 [19, 
4117] 
OUD dx timing (first 
MAT) 
n (%) Median days 
[range] 
n (%) Median days 
[range] 
n (%) Median days 
[range] 
n (%) Median days 
[range] 
First OUD dx before first 
MAT visit 
189 (36.6) 764 [1, 7499] 105 (35.0) 921 [6, 7499] 84 (38.7) 618.5 [1, 4899] 40 (48.8) 897 [1, 4899] 
First OUD dx on same day 
as first MAT visit 
328 (63.4) 195 (65.0) 133 (61.3) 42 (51.2) 
First Bup and MAT timing n (%) Median [range] n (%) Median [range] n (%) Median [range] n (%) Median [range] 
First Bup order before first 
MAT visit 
49 (9.5) 1046 [1, 5393] 19 (6.3) 217 [1, 4511] 30 (13.8) 2870.5 [4, 5393] 9 (10.9) 477 [15, 5377] 
First Bup order on same 
day as first MAT visit 
438 (84.7) 265 (88.3) 173 (79.7) 67 (81.7) 
First Bup order after first 
MAT visit 











4.2 Proportions for each covariate and standardized differences comparing opioid use disorder without any prior depression and opioid 
use disorder with any prior depression before and after weighting for all prior diagnoses limited to patients with at least a year of 
observation prior to first opioid use disorder diagnosis-Not including prior buprenorphine prescription 
  Crude (Unweighted) Weighted (stabilized)b 




















Age Category         
  18-29 37.0 32.7 4.3 -0.090 35.8 37.5 1.7 0.036 
  30-39 36.3 36.3 0.0 0.021 36.3 35.7 0.6 -0.013 
  40-49 16.3 16.1 0.2 -0.006 16.1 16.1 0.0 0.001 
  50+ 10.3 11.8 0.5 0.107 11.8 10.7 1.1 -0.034 
Male sex 57.3 38.7 18.6 -0.379 48.9 48.5 0.4 -0.008 
Non-Hispanic 
Ethnicity 
99.0 97.7 1.3 -0.103 97.7 97.8 0.1 0.007 
White race 99.3 99.5 0.2 0.027 99.5 99.6 0.1 0.016 
Prior MH dx 37.0 79.7 42.7 0.960 55.3 56.6 1.3 0.030 
Prior SU dxa 64.7 88.0 23.3 0.570 75.3 77.2 1.9 0.046 
Prior Med dxa 31.0 47.9 16.9 0.351 38.1 39.0 0.9 0.018 
Prior HIV/ Hep C dxa 9.0 11.5 2.5 0.083 11.3 12.0 0.7 0.025 
Prior chronic pain dxa 20.3 30.9 10.6 0.243 25.8 26.3 0.5 0.012 
a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior 
















4.3 Proportions for each covariate and standardized differences comparing opioid use disorder without past year depression and opioid 
use disorder with past year depression before and after weighting for all past year diagnoses limited to patients with at least a year of 
observation prior to first opioid use disorder diagnosis--Not including past year buprenorphine prescription 
  Crude (Unweighted) Weighted (stabilized)b 
  OUD wo past 
year DEP 
(n=300) 








OUD wo past 
year DEP 
(n=298) 








Age Category         
  18-29 37.0 34.2 2.8 -0.059 34.9 39.7 4.8 0.101 
  30-39 36.3 39.0 2.7 0.055 38.8 39.4 0.6 0.012 
  40-49 16.3 15.9 0.4 -0.013 15.4 8.8 6.6 -0.179 
  50+ 10.3 11.0 0.7 0.021 10.9 12.1 1.2 0.038 
Male sex 57.3 42.7 14.6 -0.295 54.1 37.3 16.8 -0.337 
Non-Hispanic Ethnicity 99.0 96.3 2.7 -0.176 98.5 98.0 0.5 -0.034 
White race 99.3 100.0 0.7 0.116 100.0 100.0 0.0 0.000 
Prior year MH dxa 15.0 73.2 58.2 1.439 28.2 34.3 6.1 0.153 
Prior year SU dxa 27.3 69.5 42.2 0.927 37.8 43.0 5.2 0.114 
Prior year Med dxa 13.0 39.0 26.0 0.618 19.6 23.6 4.0 0.095 
Prior year HIV/ Hep C dxa 1.7 4.9 3.2 0.118 2.2 3.6 1.4 0.079 
Prior year chronic pain dxa 6.7 23.2 16.5 0.474 9.8 10.8 1.0 0.029 
a The definition of all of these DO NOT include the day of OUD dx (e.g. within 1 year prior to first OUD dx date) 
b Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior year MI dx, prior year SUD dx, prior year 















4.4 Recurrent events survival analysis hazard ratios with 95% confidence intervals (CI) for comparing incidence of treatment gaps and discontinuation 
between adults with OUD without prior depression (reference) and OUD with any prior/past year depression 
a Crude N=517; IPTW N=512 
b Crude N=382; IPTW N=370 
c Cox proportional hazards model: the Prentice, Williams and Peterson (PWP) was used to estimate crude and stabilized IPTW hazard ratios  
d Stabilized IPTW for all prior depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior SUD 
dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
e All prior depression regression model adjusted for time since first OUD diagnosis and time since first buprenorphine prescription (if occurred prior) 
f Stabilized IPTW for past year depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past 
year SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered) 
g Past year regression model adjusted for sex, time since first OUD diagnosis, and time since first buprenorphine prescription (if occurred prior) 
 
 




rate per 1000 
person-years 
Crude Hazard 







rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 251 1.86 1.23 [0.95, 1.59] 1.51 [1.12, 
2.04] 
110 0.82 1.20 [0.81, 1.78] 1.50 [0.93, 2.42] 
Past year depressionb 188 1.84 1.36 [0.98, 1.90] 2.13 [1.42 3.19] 87 0.85 1.59 [0.98, 2.59] 2.01 [1.05, 3.83] 
a Crude N=517; IPTW N=512 
b Crude N=382; IPTW N=370 
c Cox regression survival analysis for recurrent events, accounting for clustering of multiple encounters per person used to estimate crude and stabilized IPTW 
hazard ratios  
d Stabilized IPTW for all prior depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior SUD 
dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
e All prior depression regression model adjusted for time since first OUD diagnosis and time since first buprenorphine prescription (if occurred prior) 
f Stabilized IPTW for past year depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past 
year SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered) 
g Past year regression model adjusted for sex, time since first OUD diagnosis, and time since first buprenorphine prescription (if occurred prior) 
 
 




rate per 1000 
person-years 
Crude Hazard 








rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 251 1.86 0.85  [0.64, 1.12] 0.80 [0.59, 1.09] 110 0.82 1.01 [0.68, 1.51] 0.75 [0.47, 1.20] 
Past year depressionb 188 1.84 0.83 [0.52, 1.35] 0.84 [0.58, 1.22] 87 0.85 1.13 [0.77, 1.64] 1.09 [0.70, 1.69] 
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4.5 Recurrent events survival analysis hazard ratios with 95% confidence intervals (CI) for comparing incidence of treatment gaps and discontinuation 
between adults with OUD without prior depression (reference) and OUD with any prior/past year depression—not adjusting for time since OUD 
diagnosis or time since first buprenorphine prescription (if occurred prior) 
a Crude N=517; IPTW N=512 
b Crude N=382; IPTW N=370 
c  Cox proportional hazards model: the Prentice, Williams and Peterson (PWP) used to estimate crude and stabilized IPTW hazard ratios 
d All prior depression stabilized IPTW included the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
e Past year depression stabilized IPTW included the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year 
SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered) 
 
 














rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 251 1.86 1.23 [0.95, 1.59] 1.50 [1.12, 2.03] 110 0.82 1.20 [0.81, 1.78] 1.44 [0.89, 2.35] 
Past year depressionb 188 1.84 1.36 [0.98, 1.90] 2.22 [1.47, 3.34] 87 0.85 1.59 [0.98, 2.59] 2.13 [1.13, 4.03] 
a Crude N=517; IPTW N=512 
b Crude N=382; IPTW N=370 
c Cox regression survival analysis for recurrent events, accounting for clustering of multiple encounters per person used to estimate crude and stabilized IPTW 
hazard ratios  
d All prior depression stabilized IPTW included the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
e Past year depression stabilized IPTW included the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year 





















rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 251 1.86 0.85  [0.64, 1.12] 0.53 [0.26, 1.08] 110 0.82 1.01 [0.68, 1.51] 0.78 [0.48, 1.28] 
Past year depressionb 188 1.84 0.83 [0.52, 1.35] 0.76 [0.47, 1.23] 87 0.85 1.13 [0.77, 1.64] 1.09 [0.71, 1.68] 
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4.6 First event survival analysis hazard ratios with 95% confidence intervals (CI) for comparing incidence of treatment gaps and discontinuation 
between adults with OUD without prior depression (reference) and OUD with any prior/past year depression—not adjusting for time since OUD 
diagnosis or time since first buprenorphine prescription (if occurred prior) 
 














rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 189 1.95 1.25 [0.94, 1.66] 1.58 [1.14, 2.17] 95 0.85 1.22 [0.81, 1.82] 1.57 [0.97, 2.54] 
Past year depressionb 139 1.90 1.37 [0.95, 2.00] 1.91 [1.24, 2.94] 73 0.87 1.60 [0.97 2.65] 2.23 [1.20, 4.13] 
a Crude N=517: IPTW N=512 
b Crude N=382; IPTW N=370 
c Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
d Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year 

























4.7 Buprenorphine retention and discontinuation comparing adults with OUD without prior depression and those with OUD any prior/past year 
depression excluding patients with any extended release formulations (Any prior depression: N=517, Past year depression: N=382)-- not adjusting for 
time since OUD diagnosis, time since first buprenorphine prescription (if occurred prior), or time between first and last MAT clinic date 
a Within first year of first buprenorphine prescription 
b Defined as 30 or more days between buprenorphine prescriptions  
c Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx 
d Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year 
  SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx 




4.8 Buprenorphine retention and discontinuation comparing adults with OUD without prior depression and those with OUD any prior/past year 
depression, excluding patients with first buprenorphine date after first date of medication-based treatment clinic visit (Any prior depression: N=487, Past 
year depression: N=360) 
a Continuous (no gaps or discontinuation) 
b Defined as 30 or more days between buprenorphine prescriptions (60 days for extended release formulations) 
c Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx 
d Regression model adjusted for time since first OUD diagnosis, time since first buprenorphine prescription (if occurred prior) and time between first and last 
medication-based clinic visit 
e Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year 
  SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx 
f Doubly robust model including sex, age categories 19-29 and 40-49, past year mental health disorder and past year substance use disorder in propensity score 




 180 day retentiona Any discontinuationb 
 OR [95% CI] Weighted OR [95% CI]c OR [95% CI] Weighted OR [95% CI]d 
Any prior depression 1.19 [0.82, 1.72] 0.92 [0.58, 1.47] 1.77 [1.13, 2.76] 2.35 [1.37, 4.04] 
Past year depression 1.69 [0.99, 2.88] 1.38 [0.63, 3.01]e 2.02 [1.10, 3.71] 2.83 [1.26, 6.34]e 
 180 day retentiona Any discontinuationb 
 OR [95% CI] Weighted OR [95% CI]c,d OR [95% CI] Weighted OR [95% CI]d,e 
Any prior depression 1.16 [0.80, 1.68] 0.59 [0.33, 1.06] 1.28 [0.80, 2.03] 1.73 [0.96, 3.13] 
Past year depression 1.59 [0.96, 2.65] 0.41 [0.16, 1.05]f 1.93 [1.06, 3.48] 2.34 [0.96, 5.71]f 
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4.9 Hazard ratios with 95% confidence intervals (CI) for comparing incidence of treatment gaps and discontinuation between adults with OUD without 
prior depression (reference) and OUD with any prior/past year depression, excluding patients with first buprenorphine date after first date of medication-
based treatment clinic visit 














rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 176 1.96 1.19 [0.89, 1.60] 1.45 [1.03, 2.05] 88 0.85 1.19 [0.78, 1.80] 1.64 [0.99, 2.70] 
Past year depressionb 131 1.93 1.32 [0.90, 1.95] 1.64 [1.03, 2.62] 68 0.87 1.57 [0.93, 2.65] 1.85 [0.96, 3.54] 
a Crude N=487; IPTW N=480 
b Crude N=360; IPTW N=348 
c Stabilized IPTW for all prior depression; adjusted for the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior SUD 
dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
d Stabilized IPTW for past year depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past 
year SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered) 
e For all prior depression, regression model adjusted for time since first OUD diagnosis and time since first buprenorphine prescription (if occurred prior) 
f For past year depression, regression model adjusted for sex, age categories 19-29 and 40-49, past year mental health disorder and past year substance use 






















4.10 Proportions for each covariate and standardized differences comparing opioid use disorder without any prior depression and opioid use disorder 
with any prior depression before and after weighting for all prior diagnoses limited to patients with at least a year of observation prior to first opioid use 
disorder diagnosis and no extended release buprenorphine prescriptions 
  Crude (Unweighted) Weighted (stabilized)b 




















Age Category         
  18-29 37.1 30.9 6.2 -0.130 35.0 37.4 2.4 0.052 
  30-39 35.3 36.6 1.3 0.027 36.3 34.4 1.9 -0.039 
  40-49 16.8 17.5 0.7 0.020 16.5 16.7 0.2 0.005 
  50+ 10.8 14.9 4.1 0.123 12.2 11.5 0.7 -0.022 
Male sex 58.4 39.7 18.7 -0.380 50.9 49.6 1.3 -0.026 
Non-Hispanic Ethnicity 99.0 97.4 1.6 -0.115 97.4 97.5 0.1 0.004 
White race 99.3 99.5 0.2 0.024 99.4 99.6 0.2 0.015 
Prior MH dx 35.7 78.9 43.2 0.969 53.7 55.3 1.6 0.037 
Prior SU dxa 64.7 88.1 23.4 0.574 75.1 76.0 0.9 0.022 
Prior Med dxa 31.8 46.4 14.6 0.301 37.0 37.7 0.7 0.014 
Prior HIV/ Hep C dxa 9.4 11.3 1.9 0.062 11.4 11.9 0.5 0.016 
Prior chronic pain dxa 20.3 32.0 11.7 0.268 25.6 26.4 0.8 0.019 
Prior buprenorphine rxa 3.5 11.9 8.4 0.317 7.1 7.5 0.4 0.016 
a The definition of all of these DO NOT include the day of OUD dx (e.g. Prior to first OUD dx date) 
b Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior MI dx, prior SUD dx, prior Medical dx, prior 

















4.11 Proportions for each covariate and standardized differences comparing opioid use disorder without prior depression and opioid use disorder with 
past year depression before and after weighting for all past year diagnoses limited to patients with at least a year of observation prior to first opioid use 
disorder diagnosis and no extended release buprenorphine prescriptions 
a The definition of all of these DO NOT include the day of OUD dx (e.g. within 1 year prior to first OUD dx date) 
b Stabilized inverse probability treatment weights; Includes the following covariates: age, race, ethnicity, sex, prior year MI dx, prior year SUD dx, prior year 
















  Crude (Unweighted) Weighted (stabilized)b 
  OUD wo past 
year DEP 
(n=286) 







OUD wo past 
year DEP 
(n=284) 







Age Category         
  18-29 37.1 30.4 6.6 -0.140 34.9 41.2 6.3 0.134 
  30-39 35.3 39.1 3.8 0.079 37.2 32.8 4.4 -0.092 
  40-49 16.8 17.4 0.6 0.016 15.8 9.6 6.2 -0.164 
  50+ 10.8 13.0 2.2 0.068 12.1 16.4 4.3 0.132 
Male sex 58.4 44.9 13.5 -0.271 55.8 30.0 25.8 -0.519 
Non-Hispanic Ethnicity 99.0 95.7 3.3 -0.203 98.4 97.4 1.0 -0.066 
White race 99.3 100.0 0.7 0.118 100.0 100.0 0.0 0.000 
Prior year MH dxa 14.0 75.4 61.4 1.561 26.1 35.8 9.7 0.245 
Prior year SU dxa 26.6 72.5 45.9 1.028 36.8 47.6 10.8 0.242 
Prior year Med dxa 13.6 37.7 24.1 0.570 19.2 26.1 6.9 0.165 
Prior year HIV/ Hep C dxa 1.7 5.8 4.1 0.212 2.8 5.0 2.2 0.116 
Prior year chronic pain dxa 6.3 26.1 19.8 0.555 10.0 12.6 2.6 0.074 
Prior year buprenorphine rxa 0.7 2.9 2.2 0.165 1.4 1.7 0.3 0.026 
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4.12 Buprenorphine retention and discontinuation comparing adults with OUD without prior depression and those with OUD any prior/past year 
depression, excluding patients with any extended release buprenorphine prescriptions (Any prior depression: N=480, Past year depression: N=355) 
a Continuous (without gaps or discontinuation) 
b Defined as 30 or more days between buprenorphine prescriptions (60 days for extended release formulations) 
c Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior  
SUD dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx 
d Regression model adjusted for time since first OUD diagnosis, time since first buprenorphine prescription (if occurred prior) and time between first and last 
medication-based clinic visit 
e Stabilized IPTW; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past year 
  SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx 
f Doubly robust model including sex, age categories 19-29 and 40-49, past year mental health disorder and past year substance use disorder in propensity score 
weight and adjusted regression model 
 
4.13 Hazard ratios with 95% confidence intervals (CI) for comparing incidence of treatment gaps and discontinuation between adults with OUD 
without prior depression (reference) and OUD with any prior/past year depression, excluding patients with any extended release buprenorphine 
prescriptions 














rate per 1000 
person-years 
Crude Hazard 




All prior depressiona 164 1.78 1.24 [0.91, 1.68] 1.57 [1.09, 2.26] 73 0.68 1.05 [0.66, 1.67] 1.66 [0.95, 2.91] 
Past year depressionb 120 1.70 1.27 [0.84, 1.92] 1.64 [0.92, 2.94] 56 0.69 1.26 [0.68, 2.34] 1.75 [0.68, 4.51] 
a Crude N=480; IPTW N=479 
b Crude N=355; IPTW N=338 
c Stabilized IPTW for all prior depression; adjusted for the following covariates in the propensity score analysis: age, race, ethnicity, sex, prior MI dx, prior SUD 
dx, prior Medical dx, prior HIV or Hep C dx, prior chronic pain dx, prior buprenorphine prescription (ordered) 
d Stabilized IPTW for past year depression; adjusted for  the following covariates in the propensity score analysis: age, race, ethnicity, sex, past year MI dx, past 
year SUD dx, past year Medical dx, past year HIV or Hep C dx, past year chronic pain dx, past year buprenorphine prescription (ordered) 
e For all prior depression, regression model adjusted for time since first OUD diagnosis and time since first buprenorphine prescription (if occurred prior) 
f For past year depression, regression model adjusted for sex, age categories 19-29 and 40-49, past year mental health disorder and past year substance use 





 180 day retentiona Any discontinuationb 
 OR [95% CI] Weighted OR [95% CI]c,d OR [95% CI] Weighted OR [95% CI]d,e 
Any prior depression 1.19 [0.37, 1.72] 0.60 [0.32, 1.11] 1.10 [0.67, 1.83] 1.71 [0.90, 3.25] 
Past year depression 1.80 [1.06, 3.05] 0.60 [0.20, 1.83]f 1.48 [0.76, 2.90] 1.45 [0.43, 4.86]f 
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4.14 Life tables for A) any gap or discontinuation, B) Any discontinuation in the first six months of buprenorphine treatment, by depression status 
 
A. Any gap or discontinuation 
OUD only (no prior depression) (n=300)    
Month n Gap/discontinuation Lost Survival Standard error 95% confidence interval 
0 300 20 15 0.931    0.015 0.896, 0.955 
1 265 17 17 0.870 0.020 0.825, 0.904 
2 231 11 30 0.826 0.023 0.775, 0.866 
3 190 7 17 0.794 0.025 0.739, 0.838 
4 166 10 15 0.744 0.028 0.684, 0.794 
5 141 8 18 0.699 0.031 0.634, 0.754 
6 115 2 16 0.686 0.031 0.620, 0.742 
OUD + any prior depression (n=217) 
Month n Gap/discontinuation Lost Survival Standard error 95% confidence interval 
0 217 23 12 0.891 0.022 0.841, 0.926 
1 182 9 13 0.845 0.025 0.788, 0.888 
2 160 11 14 0.785 0.029 0.720, 0.836 
3 135 5 10 0.754 0.031 0.687, 0.809 
4 120 3 9 0.735 0.032 0.665, 0.792 
5 108 8 11 0.677 0.036 0.602, 0.742 
6 89 9 3 0.608 0.039 0.527, 0.679 
OUD + past year depression (n=82) 
Month n Gap/discontinuation Lost Survival Standard error 95% confidence interval 
0 82 11 3 0.863 0.038 0.767, 0.922 
1 68 4 4 0.811 0.044 0.706, 0.882 
2 60 6 2 0.729 0.051 0.614, 0.814 
3 52 2 3 0.700 0.053 0.583, 0.790 
4 47 0 2 0.700 0.053 0.583, 0.790 
5 45 3 4 0.651 0.056 0.529, 0.748 












B. Any discontinuation 
OUD only (no prior depression) (n=300)    
Month n Gap/discontinuation Lost Survival Standard error 95% confidence interval 
0 300 11 15 0.962 0.011 0.933, 0.979 
1 274 13 18 0.915 0.017 0.876, 0.942 
2 243 7 36 0.887 0.019 0.843, 0.919 
3 200 4 19 0.868 0.021 0.821, 0.904 
4 177 5 17 0.842 0.023 0.790, 0.882 
5 155 3 21 0.825 0.025 0.770, 0.868 
6 131 1 18 0.818 0.026 0.761, 0.863 
OUD + any prior depression (n=217) 
Month n Gap/discontinuation Lost Survival Standard error 95% confidence interval 
0 217 15 12 0.929 0.018 0.885, 0.957 
1 190 8 13 0.888 0.022 0.837, 0.924 
2 169 4 17 0.866 0.024 0.811, 0.906 
3 148 4 11 0.842 0.026 0.782, 0.886 
4 133 1 12 0.835 0.027 0.775, 0.881 
5 120 3 15 0.813 0.029 0.748, 0.863 
6 102 4 4 0.781 0.032 0.710, 0.836 
OUD + past year depression (n=82) 
Month n Gap/discontinuation Lost Survival Standard error 95% confidence interval 
0 82 8 3 0.901 0.033 0.811, 0.949 
1 71 4 4 0.848 0.040 0.748, 0.911 
2 63 3 3 0.807 0.045 0.700, 0.879 
3 57 3 3 0.763 0.049 0.650, 0.844 
4 51 0 2 0.763 0.049 0.650, 0.844 
5 49 2 5 0.731 0.052 0.613, 0.818 
















































5.1 Summary of findings 
 
 For the first time since the early 1900s, life expectancy in the US declined three years in a 
row, from 2014 to 2017, with drug overdose and suicide deaths contributing greatly to this 
change.126,127 The contemporary overdose epidemic has claimed the lives of over 750,000 people 
since 1999,1 not accounting for morbidity associated with substance use disorders and the 
countless number of people impacted by the epidemic over the past 20 years and prior. It has 
been especially detrimental in particular states and regions in the US, including rural 
Pennsylvania where the data from this dissertation comes from. Factors that have played a 
significant role go beyond that of just over-prescribing, but include structural, social and person-
level drivers that impact the availability of and use of opioids, and access to needed resources 
and services. While this dissertation does not dive into many of these factors, it does tackle the 
complex health needs that are often not addressed among persons with opioid use disorder, and 
substance use disorders, more broadly.  
 Psychiatric comorbidity and specifically depression is not only significant because as this 
dissertation found, the prevalence is as high as 50% among persons with OUD but also because 
of the potential role in the intersection of overdose and suicide.128 Further, while we know 
psychiatric comorbidity can impact retention in substance use disorder treatment, many questions 
remain about the specific relationship between depression and opioid agonist treatment. 
Answering these questions can help with treatment planning for persons with co-occurring 
opioid use and depressive disorders. 
 This dissertation aimed to fill the gaps in our understanding of co-occurring opioid use 
and depressive disorders by exploring personal characteristics and health conditions associated 
with the comorbidity, as well as examining utilization of healthcare services and buprenorphine 
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treatment among individuals with this comorbidity. This was done using electronic health and 
prescription medication records which allows for the capacity to assess real-world utilization 
patterns across time.  
 Overall, the analyses in this dissertation found that persons with co-occurring opioid use 
and depressive disorders have complex health needs illustrated by other medical conditions and 
health risks including lifetime overdose and suicide ideation and/or attempt. Depression may also 
play a unique role in the increased risk of emergency department encounters related to substance 
use and/or mental health problems and can potentially impact continuity of buprenorphine 
treatment. The following sections summarize the findings from each analysis, acknowledge 
strengths and limitations of each, delineate remaining research questions and future directions for 
practice, and finally present key public health implications. 
Aim 1 utilized electronic health records prior to the fall of 2019 to describe 
characteristics, health conditions and overall healthcare utilization of adults with opioid use 
disorder (OUD) in the Geisinger Health System, and compare differences between those with 
and without a lifetime co-occurring depressive disorder. This study found that 49% of the study 
sample with OUD also had a depression diagnosis in their EHR. There were also a number of 
differences between persons with and without a lifetime depression diagnosis. Persons with co-
occurring depression were more likely to be female and more likely to have other comorbid 
medical conditions, including hypertension, diabetes, chronic obstructive pulmonary disease or 
asthma. Co-occurring depression was also associated with greater odds of mental health and 
substance use disorders, other than depression and opioid use disorder, as well as increased 
likelihood of experiencing an overdose or suicidal ideation and/or suicide attempt. In regard to 
healthcare utilization, persons with depression were more likely to have ever received an 
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antidepressant medication and had a greater number of outpatient and emergency department 
encounters in their EHR.  
These findings reiterate what is known from previous studies including the association 
between depression and overdose as well as suicide. The findings also highlight other medical 
comorbidities that this population face, emphasizing the importance of addressing all health 
conditions through integrated care. Based on the greater number of emergency department visits 
among persons with co-occurring depression, we might suspect that this could be impacted by 
barriers to accessing preventative healthcare as well as the complex health needs of this 
population. In summary, other comorbidities and health risks need to be considered when 
developing treatment plans and providing healthcare services to persons with co-occurring 
opioid use disorder and depression. 
 Aim 2 of this dissertation also used EHR data for encounters that took place prior to the 
fall of 2019 to assess differences in the risk of emergency department visits and inpatient 
hospitalizations following a person’s first OUD diagnosis among patients with and without a 
preceding depression diagnosis. Of all emergency department encounters in the follow-up 
period, 73.2% included a code associated with a mental health or substance use diagnosis. This 
was also the case for 28.5% of inpatient hospitalizations. Persons with OUD and any prior 
depression had increased hazard for emergency department encounters that involved a suicidal 
ideation or suicide attempt code, as well as substance use disorder codes, other than OUD. Past 
year depression was also associated with increased risk of emergency department visits with 
mental health diagnoses. No differences were observed for inpatient hospitalizations. 
 Findings from Aim 2 provide more evidence that co-occurring psychiatric disorders, 
specifically depression, are associated with increased utilization of emergency departments. 
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These results are particularly telling for emergency department visits that included codes related 
to mental health and substance use disorders, suggesting that symptoms of these conditions could 
have been driving factors for the need to go to the emergency department. Addressing unmet 
need for mental health treatment among persons with co-occurring depression and OUD could 
help to reduce the need to utilize the emergency department.  
 Aim 3 of this dissertation utilized buprenorphine prescriptions data ordered in 2018 and 
2019 by a health provider in the Geisinger Health System for patients who initiated 
buprenorphine treatment for opioid use disorder. In these analyses, the aim was to assess if those 
with co-occurring depression had a different risk of discontinuation or gaps in buprenorphine 
treatment, as well as if there were distinctions in odds of 180-day retention. Among all patients 
in the study sample, 40% remained in buprenorphine treatment at 180 days. Results from the 
time to event analysis suggest that depression preceding OUD was associated with increased risk 
of a gap in and/or discontinuation of treatment. Those who had a depression diagnosis code 
within the year prior to OUD also had decreased odds of 180-day retention. 
 The results of Aim 3 further demonstrate the complexity of co-occurring opioid use and 
depressive disorders and its impact on opioid agonist treatment. While depressive symptoms may 
decrease because of antidepressant properties of buprenorphine, having a prior depression 
diagnosis negatively impacts treatment continuity among this sample receiving care at an 
outpatient treatment center. Therefore, assessing depressive symptoms and incorporating care 
could help to reduce gaps in buprenorphine treatment and increase length of care. 
5.2 Strengths and limitations 
 
 There are a number of strengths and limitations of this dissertation that need to be 
acknowledged. First, the analyses included in the dissertation help to fill important gaps in the 
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literature, related to co-occurring opioid use and depressive disorders. Second, as states such as 
Pennsylvania that have been particularly impacted by the opioid crisis continue to work to find 
solutions and improve the health of those affected, this work can provide information to health 
systems like Geisinger to help understand how depression might impact utilization and treatment 
continuity. Further, implications for practice could include assessing and managing depressive 
symptoms as patients progress with buprenorphine treatment. 
 The use of electronic health records and prescription medication data from a large 
integrated health system is valuable to explore real-world patterns of healthcare utilization and 
treatment for opioid use disorder. By using these records, we can explore these outcomes at the 
patient-level and across time as people engage in the healthcare system. Further, a strength of 
Geisinger, in particular, is the integration of the outpatient substance use treatment clinic data 
with other primary and specialty care clinic data. The integration is made possible with patient 
consent; which allows for continuity of care across the system for these patients as well as 
allowing for work such as this dissertation to be conducted. Because of this, data from all 
specialties including outpatient substance use treatment is integrated into the electronic health 
record with patient consent; which allows for work such as this dissertation to be conducted. In 
addition to the strengths of the data, there are also notable strengths of the research methods 
implemented. Specifically, to help deal with overt biases that can exist with observational data, 
propensity score methods were implemented. Using time to event modeling also created the 
ability to assess how depression affects time to each outcome explored.  
 Despite the strengths of using electronic health and prescription medication records, a 
number of limitations of these data exist. First because these data come from a specific health 
system in Pennsylvania, healthcare utilization and buprenorphine treatment outcomes may not 
 115 
directly translate to other health systems and treatment clinics in other states because of 
differences in system policies and protocols. Related to generalizability, while the distribution of 
demographic characteristics of the study population is similar to that of the distribution across 
Pennsylvania, the sample includes almost entirely non-Hispanic white patients receiving 
healthcare in rural areas which limits generalizability to more racially diverse and urban 
populations. Limitations related to measurement are also important to address. For each of the 
aims, diagnostic codes were utilized to define exposure groups and other covariates. These 
diagnosis codes rely on the consistency and accuracy of recordings by healthcare providers. 
However, because this population was recruited from an outpatient substance use treatment 
clinic, addiction specialists verified the OUD diagnosis. Because administrative data are not 
collected for research purposes, there also could have been unmeasured factors not included in 
the electronic health and prescription medication records. Additionally, available information is 
limited to what is included in the EHR and prescription medical records. This is influenced by 
patient interactions with a health care system as well as what types of services are provided 
within the system. Lastly, the data are observational and therefore causality could not be 
examined. 
5.3 Future directions for research and practice 
 
 While this dissertation helps to fill important gaps in the existing literature, in many ways 
it generates more questions for future research and practice. These questions are separated into 
two sections below: 1) healthcare service integration; 2) treatment for opioid use disorder. 
Healthcare service integration 
 As depicted in this dissertation, persons with co-occurring OUD and depression have 
other co-occurring health conditions and therefore would greatly benefit from integrated care. 
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While treatment systems for mental illness, substance use disorders and other medical care have 
historically been independent,129 integrative care models exist to reduce barriers associated with 
separate care and address the complex health needs by creating an integrated treatment plan that 
addresses all health conditions.130 Health systems like Geisinger may be well positioned to 
ensure the implementation of integrated care. Future research should examine effects of 
integrated care on emergency department use and inpatient hospitalizations for substance use and 
mental health related conditions. 
 Additionally, results indicate that persons with co-occurring depression had an increased 
risk of utilizing the emergency department. In light of the opioid epidemic, there is increased 
attention on the role of emergency departments in reducing harms associated with opioid use and 
preventing overdose death. A number of emergency department protocols and interventions 
exist, including distributing naloxone, the use of peer navigators, initiating buprenorphine 
treatment, and linkage to other needed care.131,132 Integrated health systems, like Geisinger 
should utilize these emergency department interventions and ensure linkage to and coordination 
with outpatient treatment clinics to create more continuity of care and remove barriers to needed 
treatment and medical care. 
Treatment for opioid use disorder 
 This dissertation includes adults who have accessed healthcare services and initiated 
buprenorphine treatment within the Geisinger Health System. However, less than 20% of persons 
with an opioid use disorder receive any type of treatment for OUD133 and among those who 
receive treatment, less than 30% receive opioid agonist medications as part of their treatment 
plan.113 Persons who have comorbid depression also face unique barriers to accessing treatment 
for their mental health and substance use disorders.23 More research is needed to understand 
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barriers specific to opioid agonist treatment among this population, as well as the potential 
impact of co-occurring depression on likelihood of initiating treatment that includes medication 
to treat OUD. Additionally, while the use of buprenorphine to treat OUD has increased in recent 
years,35 it is not clear if this is the case among persons with co-occurring depression.  
 Lastly, more research is needed to investigate and improve treatment for OUD involving 
medications for persons with co-occurring depression. Because of the antidepressant properties 
of buprenorphine,124,125 the associations that exist for depression and buprenorphine treatment 
continuity and retention may not be generalizable to the two other medications used to treat 
OUD- methadone and naltrexone. While all act through the endogenous opioid system, 
pharmacodynamics differ for these medications.  
 Significant for the association with depression, buprenorphine is a partial agonist at the 
mu receptor and an antagonist at the kappa receptor. Mu receptors are responsible for euphoric 
and analgesic effects, whereas kappa receptors antagonize mu activity and produce dysphoria, as 
well as some analgesic effects. Buprenorphine’s kappa antagonism is what is argued to have the 
antidepressant effects.58,125 While naltrexone also has kappa receptor antagonism properties, its 
affinity for kappa receptors is lower than it is for mu receptors. Naltrexone’s ability to counteract 
increased activity at the kappa system is also thought to be weaker, therefore having less effect 
on mood symptoms.59 In addition to the pharmacodynamics, processes for receiving and 
administering methadone, buprenorphine and naltrexone differ.  
 Naltrexone and buprenorphine treatment are typically administered through outpatient 
medical facilities, whereas methadone is administered at opioid treatment programs. Barriers 
related to stigma, dosing and prescribing restrictions are also prevelant.44 Differences in retention 
and adherence also exist, particularly for naltrexone which requires patients to be abstinent from 
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opioids for one week prior to induction.109 Future research should continue to explore the effects 
of buprenorphine on changes in depressive symptoms and how these changes might impact 
buprenorphine treatment continuity, retention and opioid-related outcomes. More evidence is 
needed to understand if persons with depression respond differently to treatment with 
methadone, as well as explore the impact of differences in administration and treatment protocols 
on treatment initiation and course among those with co-occurring depression. This should also be 
considered in practice when developing treatment plans to best address the needs to each patient. 
5.4 Implications for public health 
 
 This dissertation highlights a number of public health implications. First, the studies 
highlight the need for engagement at different system levels to increase investment to expand 
treatment and healthcare services for persons with opioid use and depressive disorders. 
Removing barriers to use of medications to treat opioid use disorder, as well as to other medical 
and mental health care is imperative. This necessitates changes to regulatory barriers as well as 
increasing funding for treatment.134 The integration of care is a particular need for the population 
of focus in this dissertation. Integrated treatment models require buy-in from health systems and 
healthcare providers to ensure that barriers are removed and that patients are getting the 
individualized care they need. Promising approaches exist, including Medicaid health homes135 
and the “hub-and-spoke” model,136 but more action is needed to expand and ensure 
sustainability. Data surveillance and linkage is another public health priority. Collaboration 
across sectors, including researchers, policy makers and health system leadership is important to 
create and/or improve data collection and availability to identify risk factors, health outcomes, 
and access to and utilization of needed services. Finally, stigma against persons with substance 
use and mental health disorders remains a significant barrier. Stigma impedes access to and 
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utilization of evidence-based services both at the system and provider levels, and negatively 
impacts support for public health oriented policies related to opioid use.137 Persons with co-
occurring disorders are at particular risk for being impacted by stigma. Ongoing efforts to create 
policies and practices to eliminate stigma toward persons with substance use and mental health 
disorders should continue to be a focus as we implement strategies to address the ongoing opioid 
crisis in the US and work to improve health and well-being of persons with co-occurring opioid 
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